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Resumo 
 
A doença do sono em humanos é causada pelo Trypanosoma brucei, um parasita eucariota 
unicelular. Neste parasita, quase todos os genes são transcritos constitutivamente e, portanto, a sua 
regulação é sobretudo por mecanismos pós-transcricionais. A N6-metiladenosina (m6A) é uma 
modificação presente no RNA que tem sido associada à regulação da expressão génica ao nível pós-
transcricional em vários eucariotas. Com base nestas observações propus que esta modificação existe 
no transcriptoma de T. brucei e é um mecanismo de regulação da expressão génica ao nível pós-
transcricional. Neste trabalho, pela primeira vez, detetou-se esta modificação no RNA. Também 
encontrei esta modificação no DNA, sendo esta a primeira descrição de um organismo em que esta 
modificação existe nos dois tipos de ácidos nucleicos. A modificação m6A no RNA parece ser 
dinâmica: verifiquei que os níveis variam em diferentes condições biológicas, nomeadamente 
aumentam durante a diferenciação entres dois estadios do ciclo de vida e quando os parasitas são 
colocados em condições de stress provocadas por alta densidade celular. Bioinformaticamente foi 
procurado no genoma deste parasita, genes candidatos que codificam possíveis enzimas que catalisam 
a formação e a remoção desta modificação. Encontrou-se uma possível metiltransferase e seis 
possíveis demetilases. Para testar a sua possível função, foram geradas linhas celulares knockouts da 
possível metiltransferase (Tb927.7.6620) e de duas possíveis demetilases (Tb927.4.460 denominada 
TbALKBH1 e Tb927.5.980 denominada TbALKBH2). A quantificação dos níveis de m6A no RNA 
dos knockouts da metiltransferase e de uma demetilase (TbALKBH1) não revelou evidência que 
suportasse a possível função proposta. No entanto, um aumento nos níveis de m6A no RNA do 
knockout da possível demetilase TbALKBH2 indica que poderá ser uma demetilase de m6A no RNA. 
A evidência apresentada nesta tese levanta a possibilidade de um novo mecanismo de regulação pós 
transcricional em T. brucei através desta modificação no epitranscriptoma do parasita.  
 
Palavras-chave: T. brucei – modificações no RNA - N6-metiladenosina- Regulação génica 
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Abstract 
 
 Trypanosoma brucei is a unicellular eukaryote parasite that causes human sleeping 
sickness. In this parasite, transcription is mainly constitutive and gene expression regulation occurs 
essentially at post-transcriptional level. N6-methyladenosine (m6A) is an RNA modification associated 
with post-transcriptional gene regulation in eukaryotes. These observations led to the proposal that this 
modification occurs in T. brucei transcriptome and is involved in post-transcriptional gene regulation. 
In this thesis, m6A was detected for the first time in T. brucei RNA and additionally in DNA, from 
bloodstream and procyclic life stages. As far as I know, this is the first description of an organism in 
which has m6A is found in both type of nucleic acids. In RNA, I observed that the levels are regulated 
in different biological circumstances, namely, it increases during differentiation from bloodstream to 
procyclic life-cycle stages and it also increases when parasites are stressed by being placed at high cell 
density. T. brucei genome was searched with bioinformatics tools to find enzymes that catalyse the 
formation and the removal the of m6A modification in RNA. One putative RNA m6A 
methyltransferase and six putative demethylases were found. Knockout cell lines of the putative 
methyltransferase (Tb927.7.6620) and of two putative demethylases (Tb927.4.460 named TbALKBH1 
and Tb927.5.980 named TbALKBH2) were generated to test their putative functions. Quantification 
of m6A levels in RNA from the knockout cell lines did not reveal evidence that support the putative 
function of the methyltransferase and one demethylase (TbALKBH1). However, knockout of 
TbALKBH2 resulted in a slight increase in m6A levels, suggesting that this candidate could be an 
RNA m6A demethylase. The evidence presented in this thesis raises the possibility of post-
transcriptional gene regulation mediated by the presence of m6A modification in T. brucei 
epitranscriptome. 
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x 
 
  
xi 
 
Contents 
Agradecimentos ....................................................................................................................................... v 
Resumo ................................................................................................................................................... vii 
Abstract ................................................................................................................................................... ix 
Index of figures ...................................................................................................................................... xiii 
Index of tables ........................................................................................................................................ xv 
Abbreviations ........................................................................................................................................ xvi 
1.Introduction .......................................................................................................................................... 1 
1.1 Trypanosoma brucei ...................................................................................................................... 1 
1.1.1. Human African trypanosomiasis and human infective subspecies ....................................... 1 
1.1.2. T. brucei life cycle .................................................................................................................. 2 
1.1.3. Genome Organization in T. brucei ......................................................................................... 3 
1.1.4. Gene expression in T. brucei ................................................................................................. 4 
1.2. N6-methyladenosine (m6A) in RNA .............................................................................................. 8 
1.2.1. RNA modifications ................................................................................................................. 8 
1.2.2. N6-methyladenosine ........................................................................................................... 11 
1.2.3. Chemical reactions .............................................................................................................. 11 
1.2.4. Enzymes and Reversibility ................................................................................................... 12 
1.2.5. Biological functions ............................................................................................................. 14 
1.2.6. Molecular mechanisms and targets .................................................................................... 15 
1.3. Objectives ................................................................................................................................... 17 
2. Methods ............................................................................................................................................ 19 
2.1. Parasite culture .......................................................................................................................... 19 
2.2. Differentiation ............................................................................................................................ 19 
2.3. RNA extraction ........................................................................................................................... 20 
2.4. DNA extraction ........................................................................................................................... 20 
2.5. Cloning ........................................................................................................................................ 20 
2.6. Transfections .............................................................................................................................. 21 
2.7. Immunoblot ................................................................................................................................ 22 
2.8. EpiQuick m6A Quantification ...................................................................................................... 23 
2.9. Bioinformatics ............................................................................................................................ 23 
3. Results ............................................................................................................................................... 25 
3.1. Immunoblot detection of m6A in T. brucei RNA ......................................................................... 25 
3.2. Detection and quantification of m6A in T. brucei (in bloodstream and procyclic forms) .......... 28 
3.3. Levels of m6A during differentiation .......................................................................................... 30 
xii 
 
3.4. Levels of m6A in density stress condition ................................................................................... 32 
3.5. Characterization of putative m6A methyltransferase and demethylases enzymes ................... 33 
3.5.1. Identification of putative RNA m6A methyltransferase....................................................... 33 
3.5.2. Identification of putative RNA m6A demethylases .............................................................. 35 
3.5.3. Generation of knockout cell lines of putative enzymes ...................................................... 38 
3.5.4. Measurement of m6A levels in knockout cell lines ............................................................. 45 
4. Discussion .......................................................................................................................................... 47 
4.1. N6-methyladenosine (m6A) in RNA of T. brucei ......................................................................... 47 
4.2. N6-methyladenosine (m6A) in DNA of T. brucei ......................................................................... 48 
4.3. Levels of RNA m6A during differentiation .................................................................................. 49 
4.4. m6A RNA modification is sensitive to cell density ...................................................................... 50 
4.5. Putative RNA m6A methyltransferase ........................................................................................ 51 
4.6. Putative RNA m6A demethylases................................................................................................ 52 
5. Conclusion ......................................................................................................................................... 55 
6. References ......................................................................................................................................... 56 
7. Annexes ............................................................................................................................................. 66 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xiii 
 
Index of figures  
 
Figure 1.1: Human African trypanosomiasis distribution.……………………………………….……..2 
Figure 1.2: T. brucei life cycle ………………………………………………………………………….3 
Figure 1.3: Ribonucleoside modifications found in RNA ………………………...……………………10 
Figure 1.4: N6-methyladenosine structure…………………………………………………..…………11 
Figure 1.5: RNA m6A methylation/demethylation pathway…………………………………….….…13 
Figure 1.6: Molecular mechanisms and functions of m6A ………….…….….……………..……..… 16 
Figure 3.1: Immunoblot to detect m6A ………………….…………………….…………..………… 26 
Figure 3.2: Levels of m6A in total RNA from T. brucei ………...……………………………..….…… 30 
Figure 3.3: Flow cytometry of differentiated cells ………………………………………...………… 31 
Figure 3.4: Levels of m6A in total RNA during in vitro differentiation ……………………..…………31 
Figure 3.5: Levels of m6A of T. brucei from high density culture ………………………….….……..32 
Figure 3.6: MSA of sequences of the Probable N6-adenine methyltransferases ………...…………... 35 
Figure 3.7: MSA of AlkB, ALKBH and TbALKBH proteins…….…..……………………………… 37 
Figure 3.8: KO cell lines generation strategy ……………………………………...………………… 38 
Figure 3.9: Agarose gel of the inserts to clone pIV vectors…………..…………….……...………… 40 
Figure 3.10: Agarose gel of the vectors digestion …………………………………………………… 40 
Figure 3.11: Agarose gel of resistance genes integration in Tb.927.5.980 locus ……………….…… 41 
Figure 3.12: Agarose gel of resistance genes integration in Tb.927.4.460 locus…………….……… 42 
Figure.3.13: Agarose gel of resistance genes integration in Tb.927.7.6620 locus ………….……..… 42 
Figure 3.14: Agarose gel of KO cell lines locus ………………………………………….…………… 43 
Figure 3.15: Growth curve of KO cell lines ………………………………………..…………..………44 
Figure 3.16: Levels of m6A in total RNA in the generated KO cell lines ……………...…………….....46 
 
 
 
 
 
 
 
xiv 
 
  
xv 
 
 
Index of tables 
 
Table 3.1: Samples spotted in immunoblot membrane…………………………………………….….26 
 Table 3.2: Detection of m6A in RNA and DNA samples………………………………..……….….. 29 
Table 3.3: T. brucei proteins with 2OG-Fe(II) oxygenase domain ………….………..……….…….. 36 
Table 3.4: Vectors designed to KO the candidate genes …………………………….……..…………39 
Table 3.5: Inserts to generate the pIVs vectors ………………………………………..………….….. 39 
Table 3.6: Restriction digestions to confirm the cloned plasmids ……………………….………..…..40 
Table 3.7: Amplifications of resistance genes integration in Tb927.5.980 locus ……………..…….. .41 
Table 3.8: Amplifications of resistance genes integration in Tb927.4.460 locus ………………...….. 42 
Table 3.9: Amplifications of resistance genes integration in Tb927.7.6620 locus …………………... 42 
Table 3.10: Amplifications of the three candidate genes locus …………………………….………....43 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xvi 
 
Abbreviations 
AAT: Animal African trypanosomiasis 
ALBA: Acetylation lowers binding affinity 
ALKBH: AlkB homologue 
BLAST: Basic Local Alignment Search Tool 
Bp: Base pair  
BSF: Bloodstream form 
CNS: Central nervous system 
DALYs: Disability-adjusted life years 
DNA: Deoxyribonucleic Acid 
DNase I: Deoxyribonuclease I 
ECL: Enhanced chemiluminescence  
EP: EP procyclins 
E-value: Expect value 
FTO: Fat and mass associated protein 
GPEETS: GPEET procyclins 
HAT: Human African trypanosomiasis 
HMM: Hidden Markov Model 
IME4: Inducer of Meiosis 4 
KO: Knockout  
lncRNA: long non-coding RNA 
m5C: 5-methylcytosine 
m6A: N6-methyladenosine 
m7G: 7-methylguanosine 
Me-RIP: m6A-specific methylated RNA 
immunoprecipitation 
METTL14: Methyltransferase like 14 
METTL3: Methyltransferase like 3 
miRNA: Micro RNA 
mRNA: Messenger Ribonucleic Acid 
MSA: Multiple sequence alignment 
MTA: mRNA adenosine methylase 
ncRNA: Non-coding RNA 
NEB: New England Biolabs 
NPC: Nuclear pore complex 
ORF: Open reading frame 
PC: Procyclic form 
PCR: Polymerase Chain Reaction 
Poll I: RNA polymerase I 
Poll II: RNA polymerase II 
RBP: RNA binding protein 
RNA: Ribonucleic Acid 
RNase A: Ribonuclease A 
RRM: RNA recognition motif 
rRNA: Ribosomal Ribonucleic Acid 
SAM: S-adenosylmethionine 
SL: Spliced leader 
SN2: Nucleophilic Substitution bi-molecular 
TDB: Trypanosome dilution buffer 
tRNA: Transfer Ribonucleic Acid 
TSS: Transcription start site 
TTS: Transcription termination site 
UTR: Untranslated region 
VSG: Variable surface glycoprotein  
WTAP: Wilms’ tumor 1-associating protein 
YLL: Years of life lost 
YTHF: YTH domain family
1 
 
 
 
1.Introduction 
 
1.1 Trypanosoma brucei 
 
1.1.1. Human African trypanosomiasis and human infective subspecies 
 
Trypanosoma brucei (T. brucei) is a unicellular protozoan parasite. This parasite causes the 
Human African trypanosomiasis (HAT), also known as sleeping sickness (Brun et al., 2010). This 
disease occurs in 36 sub-Saharan countries, where 6314 new cases were reported in the year of 2013 
(Franco et al., 2014). The impact caused by HAT in the population was estimated in 1.6 million 
disability-adjusted life years (DALYs) per year and 27 years of life lost (YLL) per death (WHO, 2012) 
. Clinically, HAT presents two stages: first the haemolymphatic stage, characterized by the presence of 
parasites in the blood and in the interstitial space of diverse tissues. Second the meningoencephalitic 
stage, characterized by infiltration of parasites in the central nervous system (CNS) (Brun et al., 2010; 
Kennedy, 2004). During the first stage the main symptoms are fever, pruritus, lymphadenopathy and 
hepatosplenomegaly. Sleep disturbances that result from dysregulation of the circadian rhythm is the 
major symptom of the second stage. These sleep disturbances are responsible for the attribution of the 
name sleeping sickness. If untreated, HAT ultimately leads to coma and death (Brun et al., 2010; 
Kennedy, 2004).  
 
Two subspecies of T. brucei can cause HAT, T. brucei rhodesiense (East Africa) and T. brucei 
gambiense (West Africa). The distribution is represented in figure 1.1. The infection caused by T. 
brucei rhodesiense is acute, leading to death in weeks or months. As for T. brucei gambiense, the 
disease has a progressive course with a chronic infection and death occurs after several years (3-7 
years) (Brun et al., 2010; Kennedy, 2004). Parasites are transmitted to humans by the tsetse, a fly  
from the Glossina species, during its blood meal (Brun et al., 2010; Dyer et al., 2013). Besides HAT, 
this parasite also causes Animal African trypanosomiasis (AAT, or nagana) in other mammals like 
cattle (Brun et al., 2010; Steverding, 2008).  
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Figure 1.1. HAT distribution with incidence and risk for travellers indicated. Black line separate the T.b. gambiense and T. 
b. rhodesiense distribution. Adapted from (Brun et al., 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.1.2. T. brucei life cycle 
 
The life cycle of T. brucei is divided between the mammalian host and the tsetse vector 
(Figure 1.2.) (Fenn and Matthews, 2007). In the blood of the mammalian host, parasites proliferate as 
bloodstream slender forms. When the parasite population increases, cells are able to differentiate into 
non-dividing stumpy forms, using a quorum sensing mechanism (Fenn and Matthews, 2007; Matthews 
et al., 2004). Stumpy cells are competent to complete the life cycle if uptaken by the tsetse. When 
stumpy cells enter the midgut of the transmission vector, the progression of differentiation into 
procyclic forms takes place. Procyclic cells migrate to proventriculus and differentiate into 
epimastigote forms. After this event, some epimastigote cells migrate to the salivary glands of the fly, 
where they differentiate into non-dividing metacyclic forms (Dyer et al., 2013; Fenn and Matthews, 
2007). It was proposed that in the salivary glands of the tsetse, T. brucei could pass through a meiotic 
stage in the life cycle, besides the mitotic cell division (Peacock et al., 2011). When the tsetse takes 
another blood meal from a mammal, metacyclic forms are injected into its bloodstream, where the 
parasites differentiate into bloodstream slender cells closing the cycle (Matthews et al., 2004).  
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Figure 1.2. T. brucei life cycle (courtesy of Daniel Pinto-Neves. 
 
Cell differentiation throughout life cycle implies that parasites can adapt to different 
environments (Fenn and Matthews, 2007; Matthews, 2005). This adaptation is defined by alterations 
of gene expression. Comparison of the transcriptome of different life-cycle stages revealed that around 
28-40% of genes are differentially expressed between bloodstream slender forms and procyclic forms 
(Nilsson et al., 2010; Veitch et al., 2010). Consistent with these observations, recent studies comparing 
protein expression between bloodstream slender forms and procyclic forms revealed that around 33-
48% of the proteome is different (Butter et al., 2013; Gunasekera et al., 2012).  
Also during differentiation, some genes are co-regulated establishing multiple post-
transcriptional regulons. These co-regulated clusters are formed by transcripts from genes involved in 
diverse functions and some regulons are composed of genes involved in the same biochemical 
pathway. For example, genes involved in cell division and macromolecular biosynthesis are co-
regulated during differentiation, like ribosomal and flagellar proteins encoding genes (Queiroz et al., 
2009).  
 
1.1.3. Genome Organization in T. brucei 
 
T. brucei is a diploid organism whose 26 Mb genome is organized in different classes of 
chromosomes: eleven pairs of megabase chromosomes (around 1 Mb - 6 Mb), one to six intermediate 
chromosomes (200 Kb – 900 Kb) and around one hundred  minichromosomes (50 Kb - 150 Kb) (El-
Sayed et al., 2000). The megabase chromosomes have been sequenced and shown to harbour 9 068 
genes (Berriman et al., 2005). Recent studies allowed the identification of 1 114 new non-annotated 
genes (Kolev et al., 2010). Genes are organized in polycistronic units, similar to bacterial operons, but 
unlike these, genes in the same polycistronic unit do not seem be involved in the same pathway 
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(Berriman et al., 2005). Unlike megabase chromosomes, which are diploid, the intermediate 
chromosomes and minichromosomes seem to be haploid (Ersfeld, 2011). 
20% of the genes of T. brucei encode for variant surface glycoproteins (VSGs) (Cross et al., 
2014), which form a dense layer at the surface of parasite. VSGs are transcribed in a monoallelic 
fashion (Rudenko, 2010; Taylor and Rudenko, 2006), so that only one VSG coat is exposed to the 
immune system at a time. By a mechanism known as antigenic variation, some cells of the parasite 
population periodically change the expressed VSG, allowing these cells to escape the immune system 
and ensure the infection persists (Rudenko, 2010; Taylor and Rudenko, 2006). 
 
1.1.4. Gene expression in T. brucei 
 
Transcription in trypanosomes shows clear differences from “canonical” eukaryotes. Due to 
the polycistronic organization of the genes, they are transcribed as a polycistronic transcript by RNA 
polymerase II (Pol II), without any apparent transcriptional control (Clayton, 2002; Palenchar and 
Bellofatto, 2006). The polycistronic transcript is processed into individual mRNAs through a process 
called trans-splicing. In this process, a 39 nucleotide RNA cap sequence, termed spliced leader, is 
added to the 5’ end of the newly transcribed gene, while a poly-A tail is added at the 3’ end of 
upstream transcribed gene (Liang et al., 2003; Palenchar and Bellofatto, 2006). RNA polymerase I 
(Pol I) transcribes not only rRNA (18S, 5.8S and 28S), but also life-cycle stage specific proteins, 
including VSGs (in bloodstream forms) and procyclins (EPs and GPEETs, in procyclic forms) 
(Palenchar and Bellofatto, 2006). Unlike Pol II , Pol I is regulated at transcriptional level (Rudenko, 
2010). 
 
1.1.4.1. Transcriptional control in T. brucei 
 
In eukaryotes, gene expression is controlled by an interconnected net of diverse mechanisms. 
These mechanisms involve genetic elements like promoters (Juven-Gershon and Kadonaga, 2010), 
transcription factors assembly (Lemon, 2000), enhancers and silencers (Kolovos et al., 2012; Ong and 
Corces, 2011). Beyond genetic elements, gene expression is regulated by molecular mechanisms that 
do not involve changes in DNA sequence and that are called epigenetics (Goldberg et al., 2007; 
Jaenisch and Bird, 2003). Epigenetic mechanisms include DNA methylation (Bird, 2002; Jones, 
2012), non-coding RNAs (Kaikkonen et al., 2011; Mercer and Mattick, 2013), alterations in chromatin 
structure mediated by histone modifications (Bannister and Kouzarides, 2011; Kouzarides, 2007), 
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chromatin remodelling (Clapier and Cairns, 2009; Saha et al., 2006) and organization of chromatin in 
the nucleus (Fedorova and Zink, 2008; Schneider and Grosschedl, 2007). 
In T. brucei, Pol II promoters lack well-established genetic elements. The only exception is the 
promoter of the Spliced Leader gene (Schimanski et al., 2005). Besides the lack of unidentified 
promoters, very few transcription factors can be found in the genome of this parasite (Iyer et al., 
2008). Histone variants are present at transcription start sites (TSS) and transcription termination sites 
(TTS), suggesting that chromatin may play an important role in defining key functional sites of the 
chromosomes (Siegel et al., 2009). 
A wide variety of chemical modifications has been found in histones of several eukaryotes: 
acetylation, methylation, phosphorylation, ubiquitylation, sumoylation, ADP ribosylation, 
deimination, proline isomerization) (Bannister and Kouzarides, 2011). These modifications are 
dynamic. The enzymes that add the chemical modifications are called “writers” and those that remove 
are called “erasers” (Jakovcevski and Akbarian, 2012). Histone modifications can function by the 
recruitment of effectors proteins or complexes. These recruited complexes have histone modifications 
recognition domains and are called “readers” of the epigenetic code (Kouzarides, 2007; Yun et al., 
2011). T. brucei has fewer histone modifications, than most other eukaryotes  (Figueiredo et al., 2009). 
Some modifying enzymes have been characterized, including lysine acetyltransferase (MYST family 
and EPL3 homologues), deacetylases (HDAC 1-2,HDAC 3-4 and SIR2 related histone deacetylases) 
and lysine methyltransferases (Disruptor of telomerase silencing DOT1 homologues) (Figueiredo et 
al., 2009).  
In mammalian cells, DNA methylation (5-methylcytosine) is an important epigenetic mark 
that occurs mainly in CG repetitions (CpG islands) located at transcription start sites and is involved in 
gene repression (Bird, 2002). DNA methylation can also occur in other transcriptional start sites 
without CpG islands, in gene bodies, at regulatory elements and at repeat sequences (Jones, 2012). 5-
methylcytosine has also been detected in nuclear DNA of T. brucei, both in bloodstream and procyclic 
forms (Militello et al., 2008). A putative 5-methylcytosine methyltransferase has been found in the 
genome (Militello et al., 2008), but the activity was not yet empirically tested.  
Besides this DNA modification, bloodstream form of T. brucei has another unusual 
modification in its DNA, the base J (β‑d-glucopyranosyloxymethyluracil) (Gommers-ampt et al., 
1993). Base J is found mainly in the telomere repeats, repetitive sequences and transcription 
termination sites. Two base J binding proteins were found, J-binding protein 1 (JBP1) and J-binding 
protein 2 (JBP2). These base J binding proteins are required for the synthesis of base J. (Borst and 
Sabatini, 2008). In Leishmania, base J is required for proper genome wide Pol II transcription 
termination (van Luenen et al., 2012), however this genome wide function is not conserved in T. 
brucei, where base J controls transcription termination at specific locations (Reynolds et al., 2014). 
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1.1.4.2 Post-transcriptional control in T. brucei 
 
Diverse post-transcriptional mechanisms influence gene expression, including nuclear 
transport (Köhler and Hurt, 2007; Strambio-De-Castillia et al., 2010), RNA decay (Garneau et al., 
2007; Wilusz and Wilusz, 2004), and translation regulation. These processes can be mediated by the 
binding or interaction of diverse RNA binding proteins (Glisovic et al., 2008; Lunde et al., 2007) and 
non-coding RNAs with mRNAs (Kaikkonen et al., 2011).  
Nuclear transport 
mRNAs need to be transported from the nucleus to the cytoplasm, where they are translated. 
mRNAs are exported via nuclear pore complexes (NPCs), cylinder structures composed of many 
proteins that cross the double nuclear membrane. NPCs are also involved in epigenetic control of gene 
expression through interactions with the chromatin (Rodríguez-Navarro and Hurt, 2011; Strambio-De-
Castillia et al., 2010). The structure of the NPC seems to be conserved in T. brucei, suggesting that 
RNA export in T. brucei could be similar to other eukaryotes (DeGrasse et al., 2009). 
RNA stability 
RNA stability is one major factor in the regulation of gene expression. RNA stability depends 
on the interaction between several molecular mechanisms, which include untranslated regions (UTRs) 
(Mignone et al., 2002), non-coding RNAs (Kaikkonen et al., 2011) and RNA-binding proteins 
(Glisovic et al., 2008; Lunde et al., 2007). The presence in the UTRs of different motifs, recognition 
regions and secondary structures influences the interaction of proteins and non-coding RNAs. In 
general, the regulatory elements present in 5’ UTR are more associated with translation efficiency, 
while the elements in the 3’ UTR are associated with mRNA stability (Mignone et al., 2002). In T. 
brucei, diverse putative regulatory elements were found in UTRs, which could potentially regulate 
gene expression (Mao et al., 2009). Besides the presence of regulatory elements, transcripts that 
encode for the same protein could have different UTRs as result of heterogeneity in trans-splicing 
(Nilsson et al., 2010). 
RNA binding proteins 
In a cell, RNA molecules are associated to RNA binding proteins, which control RNA 
transport, decay and translation (Glisovic et al., 2008; Lunde et al., 2007). Therefore, RNA binding 
proteins are important factors in the regulation of gene expression. There are diverse RNA binding 
proteins, which are characterized by the presence of one or several RNA binding domains, including 
for example the RNA-binding domain, K-homology domain, RGG box (Glisovic et al., 2008; Lunde et 
al., 2007). T. brucei has diverse proteins with RNA binding domains, including RNA recognition 
motif (RRM), “acetylation lowers binding affinity” domains (ALBA), Pumilio domains (RBP) and 
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Zinc-Finger domains (CCCH) (Clayton, 2013; Kolev et al., 2014). RNA binding proteins are involved 
in diverse biological processes, for example overexpression of one RNA binding protein, RBP6, in 
procyclics leads to differentiation to epimastigotes and metacyclics forms (Kolev et al., 2012). 
Another example is the response to heat shock mediated by the RNA binding protein ZC3H11. This 
protein binds and stabilizes diverse mRNAs encoding heat shock proteins (Droll et al., 2013). 
RNA decay 
Steady state levels of RNAs in a cell are affected by their rate of decay (Garneau et al., 2007; 
Wilusz and Wilusz, 2004). The usual mechanisms that lead to RNA decay can be divided in three 
pathways: the deadenylation-dependent mRNA decay, in which the first step is the removal of poly A 
tail, followed by the decapping and degradation of the RNA from 5’ to 3’ end (5’3’ decay); 
alternatively, after the removal the poly A tail the degradation can start at the 3’ end (3’5’ decay); 
The other pathway is the deadenylation-independent mRNA decay, in which the decay starts with 
mRNA decapping, followed by degradation from the 5’ end; The endonuclease-mediated mRNA 
decay is the third pathway that starts with an internal cleavage of RNA by an endonuclease, followed 
by the degradation of the RNA fragments (Garneau et al., 2007; Wilusz and Wilusz, 2004). In T. 
brucei the majority of RNAs are probably degraded by a deadenylation-dependent mRNA pathway. 
(Clayton, 2014) T. brucei has deadenylation enzymes (NOT complex) (Färber et al., 2013) and 
enzymes involved in 5’3’ decay (XRNA) (Manful et al., 2011). However, no enzymes have been 
identified that could be responsible for mRNA decapping.  
Regulation by non-coding RNAs 
Diverse small non-coding RNAs regulate gene expression at the post-transcriptional level 
(Ghildiyal and Zamore, 2009). The most studied small RNAs are the micro RNAs (miRNA) and small 
interfering RNAs (siRNA), which are very similar in their biochemical properties and pathways of 
action (He and Hannon, 2004). T. brucei has an intrinsic interference RNA pathway that leads to RNA 
degradation (Ngô et al., 1998). Several components of the pathway have been identified: two DICER 
proteins (TbDCL1 and TbDCL2) (Patrick et al., 2009) and the argonaute  protein (AGO1) (Shi et al., 
2004). The small RNAs of T. brucei have around 23-26 nt and originate from diverse genomic 
sources, including natural antisense transcripts, tRNAs, rRNAs and transposable elements. (Zheng et 
al., 2013b). Bioinformatic analysis have proposed a group of putative miRNAs that could target VSGs 
(Mallick et al., 2008). 
Long non-coding RNAs (lncRNAs) can also regulate gene expression (Kung et al., 2013; 
Wilusz et al., 2009). These are RNAs which are typically longer than 200 nt and do not encode for 
proteins (Kung et al., 2013). lncRNAs can be classified based on the genomic localization from which 
they are transcribed, including long intronic ncRNAs (from introns), natural antisense transcripts 
(transcribed in the complementary strand of the ORF) and stand-alone ncRNAs (transcribed from 
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transcription units independent of ORFs) (Kung et al., 2013). The functions of lncRNAs are diverse, 
ranging from regulation of transcription, chromatin structure and nuclear organization (Wilusz et al., 
2009). At the post-transcriptional level, lncRNAs typically interact with mRNAs and this interaction 
modulates their processing, stability and translation (Kung et al., 2013).  
Cytoplasmic storage of mRNAs 
Another means of regulating gene expression is by storing and/or degrading RNA in 
cytoplasmic structures (Balagopal and Parker, 2009; Eulalio et al., 2007). RNAs can be stored without 
degradation, delaying translation, a process called translational repression. RNAs can be stored in 
constitutive structures, called P-bodies, or in temporary stress granules (Balagopal and Parker, 2009; 
Eulalio et al., 2007). T. brucei has P-bodies in the cytoplasm where RNAs are stored as part of the 
RNA processing pathway (Cassola, 2011). Stress granules are formed under heat shock and they are 
associated with the storage of transcripts. When normal grow conditions are established, stored 
mRNAs are released again to the translating pool. Starvation conditions in T. brucei lead to the 
combination of P-bodies with several ribonucleic complexes forming granules called mRNA granules, 
where transcripts are stored (Cassola, 2011). 
Translation regulation 
Protein translation is also subject to regulation. This can happen globally at the level of 
translation initiation. Translation of specific mRNAs is also dependent on the binding of proteins that 
recognize regulatory elements in the UTRs (Gebauer and Hentze, 2004). Translation efficiency is also 
important in T. brucei, varying among transcripts, in a range around 117 fold in the procyclic forms 
and around 64 fold in bloodstream form (Vasquez et al., 2014).  
 
1.2. N6-methyladenosine (m6A) in RNA 
 
1.2.1. RNA modifications 
 
More than one hundred different post-transcriptional chemical modifications have been found 
in RNA molecules, either in the four nitrogen bases or in the RNA backbone (Cantara et al., 2011; 
Machnicka et al., 2013). These chemical alterations could be the ligation of a chemical group (small or 
bulky) or an isomerization, as summarized in figure 1.3., and the same nucleotide could have more 
than one modification at the same time. Different RNA types including mRNAs, tRNAs, rRNAs, 
snRNAs and miRNAs are modified and RNA modifications are present in the three domains of life 
(Cantara et al., 2011; Machnicka et al., 2013). Potentially these modifications could modulate the 
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function, stability and information content of the RNA molecule, however the role of these 
modifications are, in general, not understood (Helm and Alfonzo, 2014; Li and Mason, 2014). In some 
cases the function of specific modifications starts to be revealed, including that of 7-methylguanosine, 
pseudouridine and 5-methylcytosine.  
7-methylguanosine (m7G, guanosine methylated in N7 position) is present in tRNA and rRNA 
in bacteria and, additionally to these RNAs types, in eukaryotes is also present in mRNA (Cantara et 
al., 2011; Machnicka et al., 2013). In eukaryotes mRNA, m7G is added to the 5’ end of the primary 
transcript through a triphosphate bridge forming a structure called cap (Cowling, 2010). These 
reactions occurs co-transcriptionally and are catalysed by capping enzymes. First, two enzymes (RNA 
5’ triphosphatase and guanylyltransferase) promote the ligation of a guanosine cap, that is methylated 
by another enzyme, the RNMT (RNA guanine-7- methyltransferase) forming the m7G cap (Cowling, 
2010). Presence of cap in 5’ end of mRNA is essential to mRNA processing, and is involved in diverse 
steps including transcription, polyadenilation, splicing, transport, stability and translation. For 
example, in splicing 5’ cap is bound by a protein complex, (cap binding complex) which interacts and 
recruits splicing complex components. To be translated, the majority of mRNAs requires the presence 
of m7G cap structure. The process occurs by the binding of eIF4F (eukaryotic initiation factor 4) to cap 
structure promoting the recruitment of ribosomal components and initiator tRNA (Cowling, 2010).  
Pseudouridine (ψ; 5-ribosyluracil) results from isomerization of uridine. The process involves 
breaking the N1-C1’covalent bound between the nitrogenous base and the ribose, followed by a 180º 
rotation of the nitrogenous base and formation of one C5-C1’ ligation between the ribose and the 
nitrogenous base (Ge and Yu, 2013). This alteration generates an additional hydrogen bond donor. 
Isomerization reaction is catalysed in specific places by box H/ACA RNAs, with some rare cases 
where it is catalysed by protein pseudouridylases (Ge and Yu, 2013). Pseudouridine is found in 
tRNAs, rRNAs, snRNAs and mRNAs, usually located in functional regions of the molecules, for 
example the peptidyl transferase center (PTC), the decoding center, the A-site finger, and subunits 
interaction sites in rRNAs (Ge and Yu, 2013). Presence of pseudouridine increases the affinity of 
rRNAs and tRNAs promoting efficient translation. In mRNAs this modification affects the codon 
specificity and, therefore, the coding potential. The three stop codons (UAA, UAG and UGA) present 
in the standard genetic code, have uridine. When the uridine is modified to pseudouridine, translation 
does not stop, an aminoacylated tRNAs binds the modified codon and translation continues, process 
denominated nonsense suppression. Presence of pseudouridine in tRNAs anticodons promotes the 
recognition of alternate codons, and potentially the pseudouridines in codons could have a similar 
effect (Ge and Yu, 2013).  
 
10 
 
5-methylcytosine is found in bacterial rRNA and eukaryotic tRNA, rRNA and mRNA 
(Cantara et al., 2011; Machnicka et al., 2013). RNA m5C methyltransferases form a large protein 
family composed of sub-families that include the RsmB family, RsmF/YebU family, Dnmt2 family, 
RlmI family, and Ynl022 family. Only some members identified in these families were empirically 
verified to 5-methylcytosine methyltransferase activity, like for example the E. coli RsmB and yeast 
Trm4 (Motorin et al., 2010). E. coli RsmB catalyse the methylation in naked 16S rRNA, but not in 
assembled 30S subunits. Yeast Trm4 catalyse the methylation in specific position of tRNA, namely 
positions 34, 40, 48 and 49. Positions 34 and 40 are only methylated in the precursors of the tRNA that 
carry the amino acids leucine and phenylalanine (Motorin et al., 2010). Biological function of m5C is 
not completely understood, although, in tRNAs, the methylated cytosine appears in specific positions 
and seems to be involved in structural conformation and stability. Degradation of tRNA is apparently 
increased in molecules lacking some methylated positions. In rRNA and mRNAs the function of m5C 
is not yet understood (Motorin et al., 2010). 
 
 
 
 
 
 
 
 
 
Figure 1.3. Representation of the ribonucleoside modifications found in RNA, the nomenclature is according MODOMICs 
database. Adapted from (Machnicka et al., 2013). 
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1.2.2. N6-methyladenosine  
 
One RNA modification is N6-methyladenosine (m6A), which differs from canonical adenosine 
by the presence of a methyl group (CH3) in the nitrogen atom linked to carbon six (N6) (Figure 1.4.). 
The presence of m6A on RNA molecules was detected in the 1970’s, in the polyadenylated RNA 
fraction. (Desrosiers et al., 1974; Perry and Kelley, 1974) and was measured to be around 0.1 to 0.4% 
of total adenosines (Darnellt, 1975; Perry and Kelley, 1975). The methylated adenosine occurs mainly 
in the consensus sequence [G/A/U]-[G/A]-A-C-[U/A/C], (where the underlined A correspond to the 
m6A) in a non-stoichiometric ratio. (Carroll SM, Narayan P, Rottman FM, 1990; Csepany et al., 1990; 
Narayan et al., 1994). In bacteria, this modification is present in rRNA, tRNA (Cantara et al., 2011) 
and adenines in DNA can also be methylated in N6 position (N6-methyladenine) (Wion and 
Casadesús, 2006). 
 
 
 
 
 
 
 
1.2.3. Chemical reactions 
 
This modified nucleoside is formed by the transfer of a methyl group from S-
adenosylmethionine (AdoMet or SAM) to adenosine. This reaction is catalysed by RNA m6A 
methyltransferases (discussed below) (Bokar et al., 1997; Liu et al., 2014). These enzymes are very 
similar to the DNA m6A methyltransferases (Bujnicki et al., 2002), therefore it is likely that the 
catalytic mechanism is preserved. Based on the crystal structure of M.TaqI, (DNA m6A 
methyltransferase from Thermus aquaticus) the reaction involves the interaction between the N6 of 
adenine to be methylated with one conserved motif (IV) in these enzymes (Goedecke et al., 2001). 
This interaction leads to the formation of hydrogen bounds between the hydrogens of amine group and 
the motif IV amino acids, promoting a hybridization change from sp2 to sp3 in the nitrogen atom. This 
leaves a free electron pair, not conjugated to the aromatic system, that attacks the methyl group in 
SAM, resulting in a nucleophilic substitution (SN2) (Goedecke et al., 2001). The reverse reaction, N6-
Fig 1.4. structures of the canonical adenosine (left) and the N6-methyladenosine (right). Adapted from  (Jia et al., 2013). 
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methyladenosine to adenosine, is catalysed by RNA m6A demethylases (discussed ahead) (Jia et al., 
2011; Zheng et al., 2013a). The mechanism proposed involves the hydroxylation (ligation of one OH) 
to the methyl group (N6 position) forming one intermediate, N6-hydroxymethyladenosine. This 
intermediate can oxidize directly to adenosine (releasing a formaldehyde molecule). Besides direct 
oxidation of N6-hydroxymethyladenosine to adenosine, this intermediate can be oxidized to a second 
intermediate, N6-formyladenosine. The adenosine is produced by the oxidation of this second 
intermediate. These two intermediates are stable at physiological conditions and were detected in 
mammalian RNA, opening the possibility that they could have additional biological functions (Fu et 
al., 2013). 
 
1.2.4. Enzymes and Reversibility 
 
From HeLa cells nuclear extracts, it was possible to partially purify a multi-subunit protein 
complex, that catalyses the RNA adenosine methylation in vitro, which is dependent of SAM (Bokar 
et al., 1994). One of the subunits of the complex, which binds to SAM, was identified as MT-A70 (or 
METTL3) (Bokar et al., 1994). Cloning of MT-A70 gene (Bokar et al., 1997) allowed bioinformatics 
analysis by phylogenetic inference, with similar sequences found in databases being clustered in four 
subfamilies (A to D). Altogether they form the MT-A70 protein family (Bujnicki et al., 2002). Fold 
recognition analysis results indicates a structure with a consensus SAM - dependent MTase fold, 
characterized by α/β/α “sandwich” with seven central β-strands. In this consensus fold, several amino-
methyltransferases characteristic motifs were identified. One of the most conserved is motif IV 
(N/D/S)-P-P-(F/W/Y/H) (Bujnicki et al., 2002). The MT-A70 protein family is very similar to the m6A 
DNA Methyltransferase families as they share the SAM - dependent MTase fold and the conserved 
motifs (Malone et al., 1995).  
Besides MT-A70, two other subunits of the m6A RNA methyltransferase complex were 
revealed: METTL14 (methyltransferase like 14) and WTAP (Wilms’ tumor 1 (WT1)-associating 
protein) (Liu et al., 2014; Ping et al., 2014; Wang et al., 2014b). METTL14 is a member of the MT-
A70 family, containing the characterized motifs  and possesses m6A RNA methyltransferase activity 
(Liu et al., 2014; Ping et al., 2014; Wang et al., 2014b). MT-A70 and METTL14 form a heterodimer  
in a 1:1 ratio and the catalytic activity of the dimer is higher than the subunits alone (Liu et al., 2014; 
Wang et al., 2014b). Knockdown of MT-A70 or METTL14 leads to a decrease in m6A levels and the 
stability of each subunit depends of the presence of the other (Liu et al., 2014; Ping et al., 2014; Wang 
et al., 2014b). The subunit WTAP does not have any m6A RNA methyltransferase domain (Ping et al., 
2014), and it does not have catalytic activity as an independent subunit either (Liu et al., 2014). 
However, WTAP interacts with the MT-A70-METTL14 heterodimer and affects its catalytic activity 
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Figure 1.5. RNA m6A methylation/demethylation pathway. Methylation is SAM dependent and 
catalysed by METTL3-METTL14 heterodimer. WTAP is a regulatory subunit of the methyltransferase 
dimer. Demethylation is catalysed by FTO or ALKBH5. Adapted from (Liu et al., 2014) 
in vivo (Liu et al., 2014; Ping et al., 2014). This suggests that this subunit has a regulatory role in the 
m6A RNA methyltransferase complex. Besides these subunits, another protein that interacts with the 
methyltransferase complex and results in a decrease of methylation after knockdown is KIAA1429 
(Schwartz et al., 2014). 
Enzymes responsible for removing m6A from RNA have also been recently identified. The 
first gene identified was the human FTO gene (which encodes for the fat and mass associated protein) 
(Jia et al., 2011). This protein demonstrates oxidative demethylation activity in vitro in dsDNA, 
ssDNA and ssRNA (Fu et al., 2013). Three dimensional crystal structure of FTO revealed that this 
protein is composed of two domains, a catalytic N-terminal AlkB-like domain and a C-terminal 
domain (now named FTO C-terminal domain). (Han et al., 2010). The observation that N6-
methyladenosine in RNA is a main substrate of FTO (Jia et al., 2011) was a breakthrough, because for 
the first time it was demonstrated that this RNA modification is reversible, a key feature of regulatory 
mechanisms. Recently a second RNA m6A demethylase, ALKBH5, was identified in humans (Zheng 
et al., 2013a). This protein is a member of the ALKBH family, a family of homologues of the bacterial 
AlkB. The demethylase catalytic activity of ALKBH5 is comparable to the FTO activity (Zheng et al., 
2013a).  
The known RNA methylation process is summarized in figure 1.5. The demonstration of 
reversibility raised the possibility of post-transcriptional gene regulation mediated by m6A and other 
RNA modifications and leads to the introduction of the concepts epitranscriptome and RNA 
epigenetics (He, 2010; Saletore et al., 2012). 
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1.2.5. Biological functions 
 
The relevance of this modification in biological systems can be addressed through the 
resulting phenotypes when the enzymes are disturbed through knockout, knockdown, mutations or 
overexpression. In HeLa cells, the lack of the methyltransferase MT-A70 results in apoptosis (Liu et 
al., 2014). Knockdown of the mouse homologue in embryonic stem cells affects the self-renewal 
capability (Wang et al., 2014b). In S. cerevisiae, m6A RNA methylation is only found in the sexual life 
stage, and the MT-A70 homologue, Ime4, is involved in the induction of meiosis and sporulation. 
Mutations that result in IME4 loss of function lead to defects in sporulation (Clancy et al., 2002). 
Besides induction of sporulation, lineage restriction is partially dependent on the activity of this gene 
(Agarwala et al., 2012). A. thaliana homologue of MT-A70, MTA is highly expressed in dividing 
tissues and essential to seed development (Zhong et al., 2008). The homologue found in D. 
melanogaster, DmIme4, is essential and affects oogenesis through notch signalling (Hongay and Orr-
Weaver, 2011).  
The FTO gene has been associated with metabolic disorders (Wang et al., 2012) and obesity 
(hence the name, at fat mass and obesity-associated) (Dina et al., 2007). Overexpression of FTO 
demethylase leads to a food intake increase and obesity in mice (Church et al., 2010) and affect 
hepatic metabolism in liver cell lines (Bravard et al., 2014). Also, the activity of the dopaminergic 
signalling in the midbrain is regulated by FTO (Hess et al., 2013). The lack of ALKBH5 demethylase 
in mice affects fertility due to the occurrence of apoptosis in spermatogenesis (Zheng et al., 2013a).  
Besides the interference of the methyltransferases/demethylases, the use of methylation 
inhibitors allows to understand the biological effects of m6A RNA methylation. Using this strategy, it 
was recently demonstrated that the circadian rhythm is affected by this modification (Fustin et al., 
2013). Circadian rhythm are biological activities, for example activity/rest behaviour, that follow a 
cycle of around twenty four hours. This rhythmic behaviour in time is due to an endogenous self-
sustained molecular clock that is synchronized with environmental stimulus and the time that the cycle 
takes is called period (Merrow et al., 2005). The inhibition of methylation as well as MT-A70 
knockdown elongates the period, while the opposite effect was observed with MT-A70 
overexpression, demonstrating that RNA m6A regulates the speed of the circadian clock (Fustin et al., 
2013)    
The fact that the perturbation of RNA methylation/demethylation balance affects diverse 
biological process in different organisms suggests that this modification has an important role in 
biological systems influencing a wide range of pathways.  
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 1.2.6. Molecular mechanisms and targets 
 
To understand the molecular mechanisms and functions of m6A RNA modification, two 
independent groups have identified the RNA molecules harbouring the modification in humans and 
mice. This was achieved by immunoprecipitation of m6A containing RNAs, followed by high 
throughput sequencing (Dominissini et al., 2012; Meyer et al., 2012). In one study, m6A was identified 
in 5,768 and 8,843 human (from HEK293T cell line), and mouse brain transcripts, respectively (Meyer 
et al., 2012). In the other study,  m6A was identified in 7,240 and 3,442 transcripts in humans (HepG2 
cell line) and mice respectively (Dominissini et al., 2012). These two studies demonstrated that this 
RNA modification is widely distributed throughout the transcriptome (Dominissini et al., 2012; Meyer 
et al., 2012). Both studies revealed that m6A is more enriched in the 3’ UTR near the stop codon, 
although peaks could also be detected within other regions of the transcripts (Dominissini et al., 2012; 
Meyer et al., 2012). Moreover, the frequent motifs found in these enriched regions agree with the 
previous biochemically determined motif (Carroll SM, Narayan P, Rottman FM, 1990; Dominissini et 
al., 2012; Meyer et al., 2012; Narayan et al., 1994). Besides human and mouse, the methylated 
transcriptome was analysed in yeast, which identified peaks in 1183 transcripts (Schwartz et al., 2013).  
In addition to the identification of the targets, the detection of m6A in several mouse tissues, 
and the increase in its levels from embryo to adult development suggest that this modification is 
widespread and dynamic (Meyer et al., 2012). Perturbation of the RNA methylation through 
knockdown of RNA methyltransferases (MT-A70, Mettl14), RNA demethylase (ALKBH5) or the 
methyltransferase regulator subunit (WTAP) followed transcriptome analysis thought RNA-Seq or 
microarray reveal diverse alterations in gene expression (Dominissini et al., 2012; Ping et al., 2014; 
Wang et al., 2014b; Zheng et al., 2013a). These observations suggests that RNA m6A methylation 
could be an epigenetic modification that regulates gene expression at post-transcriptional level. 
What is the molecular mechanism of action of m6A modification? This question does not have 
a unique answer. Multiple studies have suggested multiples mode of action: 
1. The effect of m6A in gene expression regulation could be mediated by readers of the 
epigenetic code, effector proteins that recognize and bind m6A in RNA leading to the consequence in 
the transcript (for example alteration in stability). So far, three m6A binding proteins were found in 
humans, YTHF1, YTHF2 and YTHF3 (Dominissini et al., 2012; Wang et al., 2014a). The YFTH2 
knockdown leads to an increase in the average lifetime of target transcripts and reduced translation 
efficiency, suggesting that this interaction destabilizes RNAs. In accordance with this observation, this 
protein co-localizes with markers of P-bodies (complexes involved in mRNA storage and decay) 
suggesting an involvement in mRNA decay (Wang et al., 2014a). Similar effect of m6A in reducing 
RNA stability was observed in another study, however the molecular mechanism is different. The 
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Figure 1.6. Molecular mechanisms and functions of m6A. A) to promote or block  RNA–protein interactions; B) 
to regulate RNA stability through diverse mechanisms. C) to influence splicing efficiency. Adapted from (Meyer 
and Jaffrey, 2014)  
effect is not due to a recruitment of a reader protein, but through blocking the binding of HuR, a 
protein that stabilizes RNA (Wang et al., 2014b).  
2. This modification has also been proposed to be important in splicing. The first evidence is 
that m6A methyltransferases and demethylases co-localize with nuclear speckles (complexes involved 
in pre-mRNA processing and splicing) (Jia et al., 2011; Liu et al., 2014; Zheng et al., 2013a). Second, 
some introns also contain the m6A modification (Dominissini et al., 2012; Meyer et al., 2012).  
3. Knockdown of ALKBH5 demethylase leads to an increase in the rate of mRNA export from 
the nucleus to the cytoplasm (Zheng et al., 2013a). Together with the observation that methylation 
inhibitors lead to an increase in the nuclear retention of some mRNAs, namely the circadian RNAs 
(Fustin et al., 2013), it has been proposed that m6A modification may be involved in the nuclear 
transport of RNAs.  
4. Localization of m6A in transcripts occurs mainly in 3’ UTR, near the stop codon, therefore 
localizes close to the typical binding sites of microRNAs (3’ UTR). This suggest that  m6A could 
interfere with the action of microRNAs (Meyer et al., 2012). 
Although much remains to be studied on the exact role of m6A in different organisms, it is 
clear that this RNA modification is involved in regulation of gene expression at a post-transcriptional 
level (Fu et al., 2014; Meyer and Jaffrey, 2014). Molecular mechanisms and functions proposed that 
lead the effects in transcriptome are summarized in figure 1.6. 
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1.3. Objectives 
 
In several eukaryotes recent evidence indicates that the presence of N6-methyladenosine 
(m6A) in RNA is associated to processes of post-transcriptional gene regulation. Because in T. brucei, 
gene expression is mainly regulated at the post-transcriptional level, it is reasonable to hypothesise 
that m6A RNA may be a novel mechanism of gene regulation in this parasite. In this thesis, I had four 
main objectives. First, I tested if this modification was present in RNA of trypanosomes. Then I 
determined if the levels of m6A were regulated in different biological conditions. Third, I searched the 
parasite genome to identify putative enzymes that may add or remove this modification. Finally, I used 
genetic tools to test the role of some of these enzymes. 
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2. Methods 
 
2.1. Parasite culture 
 
T. brucei brucei SMOx (Single Marker from Oxford), a modified version of the pleomorphic 
strain AnTat1.1E, which contains T7 polymerase and TET repressor, was cultured at 37°C in 5% CO2 
in HMI-11 medium (HMI-9 medium (Hirumi, 1989) without serum plus) supplemented with 
puromycin  at 0,1 µg/mL (Invitrogen cat: ant-pr-1). Cell density was maintained below 1 x 106 
cells/mL (usually cultures were passed when they reached around 0,5 x 106 cells/mL, unless stated 
otherwise). Knockout cell lines were cultured under the same conditions, with the additional drugs 
supplemented to the medium (G418 at 2,5 µg/mL (Invitrogen cat: ant-gn-5) and hygromycin at 5 
µg/mL (Invitrigen cat: ant-hm-1). Procyclic culture was cultured at 27°C in 5% CO2 in DTM medium 
(Vassella and Boshart, 1996). Cell density was maintained between 1 – 10 x 106 cells/mL. 
 
2.2. Differentiation 
 
Bloodstream culture at a density around 1-2 x106 cells/mL were centrifuged at 1800 rpm, for 
10 minutes at room temperature. Cells were re-suspended in DTM (Vassella and Boshart, 1996), at a 
cell density of 1-4 x106 cells/mL with freshly prepared cis-aconitate  (Sigma-Aldrich cat: A3412) at a 
final concentration of 6 mM. Culture was incubated at 27°C and 5% CO2.  
The efficiency of differentiation was confirmed by the expression of procyclin through flow 
cytometry. 0,5 million cells were centrifuged at 2800 rpm for 10 minutes at 4°C. The cells were 
transferred to an eppendorf tube and centrifuged again at 2800 g for 4 minutes at 4°C. Cell pellet was 
re-suspended in FITC conjugated anti-procyclin antibody (Cedarlane’s cat: CLP001F) diluted in HMI-
11 in a 1:500 dilution and incubated 15 minutes at 4°C. After incubation, the cells were spun at 2800 g 
for 4 minutes at 4°C and washed three times with HMI-11. After washing, the cells were re-suspended 
in HMI-11 and analyzed with BD LSR Fortessa (Becton Dickinson cytometers). 
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2.3. RNA extraction 
 
About 50 million parasites were centrifuged at 1800 rpm for 10 minutes at 4°C. Cells were 
transferred to eppendorf tubes and washed twice with TDB (5 mM KCl, 80 mM NaCl, 1 mM MgSO4, 
20 mM Na2HPO4, 2 mM NaH2PO4, 20 mM glucose, pH 7.4), except for procyclic cells that were 
washed with PBS (137 mM NaCl, 2.7  mM KCl, 10  mM Na2HPO4, 2 mM KH2PO4, pH 7,4). Cell 
pellets were re-suspended in TRIzol (Life Technologies, cat: 15596) and RNA was extracted 
according to the manufacturer’s instructions. RNA samples were quantified with NanoDrop 2000 
Spectrophotometer (Thermo Scientific). 0,5U of DNaseI (New England Biolabs, NEB, cat: M0303S) 
were added per µg of RNA in DNaseI buffer (NEB cat: B0303S) and incubated at 37°C for 45 
minutes. After incubation, EDTA was added to a final concentration of 5 mM and heat inactivated at 
75°C for 10 minutes. 
 
2.4. DNA extraction 
 
About 50 million parasites were spun at 1800 rpm for 10 minutes at 4°C. Cells were 
transferred to eppendorf tubes and washed twice with TDB, except for procyclics which were washed 
with PBS. Cell pellets were re-suspended in DNAzol (Life Technologies, cat: 10503-027) and DNA 
was extracted according to the manufacturer’s instructions. DNA samples were quantified with 
NanoDrop 2000 Spectrophotometer (Thermo Scientific). DNA was treated with RNase A (Carl Roth 
cat: 7156) (100 µg/mL) at 37°C for 2 hours.  
 
2.5. Cloning 
 
All pIV plasmids possess a common backbone, with an ampicillin resistance gene and an 
origin of replication for bacteria, which was obtained by digestion of pFAB2 (from Luisa Figueiredo 
Lab) with NotI-HF (NEB cat: R3189S) and KpnI-HF (NEB cat:R3142S) (CutSmart™ Buffer at 37°C, 
5 Units per µg of DNA, for 4 hours). Inserts were amplified with Phusion High-Fidelity DNA 
Polymerase (Thermo Scientific, cat: F5305) according to the manufacturer’s instructions. Inserts that 
correspond to genomic recombination sites were amplified from T. brucei genomic DNA. G418 and 
hygromycin resistance genes were amplified from pLF13 plasmid and p2T7TA, respectively (Luisa 
Figueiredo Lab). Primer sequences are described in a table in annexes. Digestion and PCR 
amplification products were purified through gel extraction with QIAquick Gel Extraction Kit 
(Quiagen cat: 28706) according to the manufacturer’s instructions. After extraction, a sample of each 
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of the fragments was run in agarose gel to confirm its purity. Fragments designed for each plasmid 
were cloned with the In-Fusion® HD Cloning Kit (Clontec cat: 639649). Briefly, 100 ng of vector 
backbone was mixed with 100 ng of an equimolar mixture of inserts. The reaction was incubated at 50 
°C for 15 minutes. This mixture was then diluted 1:5 with TE buffer (10 mM Tris-HCl, 1 mM EDTA, 
pH 8.0) and used to transform competent JM109 E. coli bacteria (Promega cat: L2001). 50 µL of E. 
coli were mixed with 5µL of diluted In-Fusion reaction and incubated at 42°C for 45 seconds and 
immediately put on ice for 2 minutes (heat shock). Then, 950 µL of SOC medium at room temperature 
was added and incubated at 37°C for 1 hour, under gentle agitation. Bacteria were centrifuged at 8000 
rpm for 2 minutes, re-suspended in 150 µL of SOC medium, plated in LB agar supplemented with 
ampicillin (100µg/mL) and incubated at 37°C overnight. Colonies obtained were grown in LB liquid 
medium overnight and the plasmid extracted with Fast-n-Easy Plasmid Mini-Prep Kit (Jena 
Bioscience cat: PP-204L) according to the manufacturer’s instructions. Isolated plasmids were 
digested to confirm if the cloned plasmids correspond to the desired plasmids. All enzymes used to 
digest the plasmids were from NEB. pIV1 was digested with EcoRI-HF (cat: R3101S)  and KpnI-HF 
(cat: R3142S), pIV2 was digested with BamHI-HF (cat: R3136S) and SacI-HF (cat: R3138S), pIV3 
was digested with BsaI-HF (cat: R3535S) and KpnI-HF (cat: R3142S), pIV4 was digested with 
EcoRI-HF (cat: R3101S) and NotI-HF (cat: R3189S), pIV5, was digested with BamHI-HF (cat: 
R3136S) and KpnI-HF (cat: R3142S)  , and  pIV6 was digested with EcoRI-HF (cat: R3101S)   and 
NotI-HF (cat: R3189S). All reactions were performed in CutSmart™ Buffer at 37°C, 5 Units per µg of 
DNA, for 4 hours. To confirm that the constructs were correctly cloned, the plasmids were sequenced 
in STAB VIDA (primer table in annexes). 
 
2.6. Transfections 
 
pIV plasmids were digested with NotI-HF (cat: R3189S) and KpnI-HF (R3142S) (from NEB), 
in CutSmart™ Buffer at 37°C, 5 Units per µg of DNA, for 4 hours (with the exception of pIV1 that 
was digested with KpnI-HF and NdeI (cat: R01115) in CutSmart™ Buffer in the same conditions). 
Digestion products were purified by ethanol precipitation. 1/10 volume of sodium acetate (3M, pH 
5,2) and 2,5 volumes of ice cold ethanol were added to each digestion reaction and incubated for 1 
hour at -80°C. After incubation, DNA was centrifuged at 13 200 rpm for 30 minutes at 4°C. DNA 
pellets were washed with 70% ethanol and centrifuged at 13 200 rpm for 10 minutes. Supernatants 
were discarded inside the flow chamber for sterility maintenance. When pellet was dry, DNA was 
ressuspended in 10 µL of mili-Q water (inside the flow chamber). 
Transfections were done by electroporation (Burkard et al., 2007). Briefly, 30 million cells 
were spun at 1800 rpm for 10 minutes at room temperature and re-suspended in 90 µL of “Roditi 
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buffer” (90mM Na-PO4, 5mM KCL, 50mM HEPES, 0.15mM CaCl2, pH 7,3). Purified DNA sample 
(5-10 µg in 10 µL) was added to the cells and the mixtures were transferred to 2mm gap cuvettes 
(BioRad Gene Pulser/MicroPulser Cuvettes). Electroporations were performed with X-001 program in 
the Amaxa Nucleofector (Lonza Cologne AG, Germany) and immediately parasites were diluted in 
HMI-11 at 37°C and plated in three plates of 24 wells, with 10-fold dilution to each plate. Plates were 
incubated at 37 °C and selection drugs were added to the wells 8-16 hours later.  Obtained clones were 
genotyped through amplification of the locus and the recombination regions, with Taq DNA 
Polymerase (Thermo Scientific), or Phusion High-Fidelity DNA Polymerase (Thermo Scientific) 
according to the manufacturer’s instructions (primers’ table in annexes).  
 
2.7. Immunoblot 
 
RNA samples were denatured by incubation at 50°C for 20 minutes and placed immediately 
on ice. DNA samples were denatured by boiling for 10 minutes and placed immediately on ice. One 
volume of 20X SSC (3 M NaCl; 0,3 M sodium citrate; pH 7) was added to each sample. Nucleic acid 
samples were spotted in a positive charged nylon membrane (Amersham Hybond™-N+ ) and fixed by 
UV crosslink (Stratalinker® UV Crosslinker, autocrosslink mode: 120 mJ/cm2 with 254 nm). 
Membranes were stained with methylene blue (0,02% in 0,3 M sodium acetate pH 5,5) and washed 
with milli-Q water to reduce background. Staining was removed by washing with distaining solution 
(0,2X SSC, 1% SDS) and washed twice with PBS/Tween 0.1% for five minutes each wash. After that, 
the membrane was blocked in 5% milk in PBS/Tween 0.1% for one hour. Blocked membrane was 
incubated with anti-m6A antibody (Millipore, rabbit polyclonal cat: ABE572) in a 1:1.000 dilution in 
3% milk in PBS/Tween 0.1% overnight at 4°C. Membrane was washed three times with PBS/Tween 
0.1% for 5 minutes each wash and incubated 45 minutes with secondary anti-rabbit IgG antibody 
(HRP-Linked, GE Healthcare) in a 1:10.000 dilution. Membrane was washed three times with 
PBS/Tween 0.1% for 5 minutes each wash and was developed by incubation for 4 minutes with Plus-
ECL reagents (enhanced chemiluminescence, PerkinElmer). Luminescence was captured in 
ChemiDoc XRS System (Bio-Rad) for 30 minutes. 
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2.8. EpiQuick m6A Quantification 
 
Detection and quantification of m6A was done with EpiQuik™ m6A RNA Methylation 
Quantification Kit (EPIGENTEK cat: P-9005) according to the manufacturer’s instructions. Briefly, 
nucleic acids were incubated in individual wells with binding solution at 37°C for 90 minutes, washed 
three times with diluted wash buffer, and incubated with the capture antibody (1:1000 dilution) for one 
hour at room temperature. The wells were washed three times with diluted wash buffer, and incubated 
with detection antibody (1:2.000 dilution) for 30 minutes at room temperature. After four washes with 
diluted wash buffer, wells were incubated with enhancer solution (1:5.000 dilution) for 30 minutes at 
room temperature. Wells were washed five times as before and developed for 5 minutes, when the 
reaction stopped. Absorbance was measured at 450 nm in a plate reader (Tecan, model Infinite M200).  
 
2.9. Bioinformatics  
 
Sequences search of putative T. brucei RNA m6A methyltransferases and demethylases was 
performed with BLAST in TriTrypDB (Aslett et al., 2010). Putative T. brucei RNA m6A 
methyltransferases and demethylases domains search was done in Pfam database (Finn et al., 2014). 
Sequences from T. brucei putative candidates were obtained from TriTrypDB and  the remain 
sequences (human ALKBH1-8, E. coli AlkB and eukaryotic containing Pfam domain PF10237 
sequences) were obtained from UniProt (Apweiler et al., 2004) . Domains from the previous described 
sequences were identified with Pfam and manually curated. Multiple sequence alignments were done 
with Clustal Omega (Sievers et al., 2011), manually edited with Jalview (Waterhouse et al., 2009) and 
colored with Chroma (Goodstadt and Ponting, 2001) with black and white default parameters (table of 
color and corresponding properties in annexes). Secondary structure was predicted with PsiPred 
(McGuffin et al., 2000) and Jpred (Cole et al., 2008). 
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3. Results 
 
In this project, I hypothesized that N6-methyladenosine modification could be an important 
mechanism to regulate gene expression in T. brucei. For that, I first tried detect m6A with an 
immunoblot assay (Section 3.1). Next I used a specific kit to detect and quantify this modification in 
two different stages of the life cycle of T. brucei (Section 3.2). In Section 3.3 and 3.4, I characterized 
the levels of m6A levels during differentiation from bloodstreem to procyclic forms and in stress 
conditions respectively. Finally, I screened for putative methyltransferase or demethylase enzymes and 
I tested their role by generating knockout mutants (Section 3.4).  
 
3.1. Immunoblot detection of m6A in T. brucei RNA 
 
My first goal was to test if N6-methyladenosine was present in nucleic acids in T. brucei of 
bloodstream forms (BSF) and procyclic forms (PC). For this, I tried to use an immunoblot method that 
applies an available m6A specific antibody. The method consists in the direct application of nucleic 
acids to a membrane (dot blot). After the ligation of the nucleic acids, the membrane is blocked and 
incubated with an anti-m6A antibody. Signal of bound anti-m6A antibody is generated by a secondary 
antibody linked to horseradish peroxidase and exposed to ECL substrate. Because m6A is present in 
RNA of some eukaryotes and the DNA of some prokaryotes, I first tested the presence of this 
modification in both type of nucleic acids of T. brucei. The negative control used consisted in a 
synthetic oligo that does not contain m6A. I also used additional RNA and DNA positive controls from 
biological samples: an RNA positive control extracted from mouse liver (C57BL/6 mouse), described 
as a tissue rich in m6A (Meyer et al., 2012), and a DNA positive control from E. coli (JM109 strain, 
Dam+), which contains this modification in its chromosomal DNA (Ratel et al., 2006). My samples 
from T. brucei were total RNA and genomic DNA. RNA samples were treated with DNaseI to remove 
possible DNA contamination, and DNA samples were treated with RNase A to remove possible RNA 
contamination. The presence of the nucleic acids in the membrane was controlled by staining with 
methylene blue. The result of the immunoblot assay was not conclusive (table 3.1, figure 2.1.). 
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Table 3.1. Samples spotted in immunoblot membrane to detect m6A in T. brucei nucleic acids 
SAMPLE DESCRIPTION 
1 Negative control, synthetic oligo 
2 Mouse liver RNA, RNA positive control 
3 E. coli DNA, DNA positive control 
4 T. brucei bloodstream RNA 
5 T. brucei bloodstream DNA 
6 T. brucei procyclic RNA 
7 T. brucei procyclic DNA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Immunoblot to detect m6A A) Methylene blue staining after loading and UV crosslink of nucleic acid samples; 
B) Anti-m6A labelling; C) Methylene blue staining after development. The number of each sample in the immunoblot is 
indicated in table 3.1.  
C 
B 
A 
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Samples were spotted in 5-fold serial dilutions from 10 µg to 0,08 µg. The first picture is 
methylene blue staining after the samples have been spotted and cross-linked to the membrane (Fig 
3.1A). First observations are that the negative control was not attached to the membrane and RNA 
samples become bound to the membrane more efficiently than DNA samples. Heterogeneity in the 
intensity of the spots staining with the same amount of sample indicates that the ligation of the nucleic 
acid to the membrane is not very efficient and part of the sample was lost.  
Blot was incubated with anti-m6A primary antibody, then with a secondary antibody and 
finally signal was developed by ECL (Figure 3.1B). The negative control did not generate signal, as 
expected, considering that in the previous methylene blue staining, it was observed that the synthetic 
oligo did not become bound to the membrane. Therefore, the negative control is not valid as it did not 
give the nucleic acid background signal. RNA positive control did not generate any signal, therefore it 
is not possible to draw any conclusion about the T. brucei RNA samples that did not generate signal. 
T. brucei DNA samples, both bloodstream and procyclic forms, generated signal, however a much 
more faint signal than the DNA positive control. Bloodstream form sample generated signal in the 
titres of 10 µg and 2 µg. Procyclic form only generated signal in the 10 µg titre. Due to the lack of 
negative control, it is not possible to understand if the faint signal observed in the T. brucei DNA 
samples are the nucleic acid background or a specific signal.  
After development the membrane was stained again with methylene blue to control for the 
possible loss of sample during the development (Figure 3.1C). The staining reveals that all the RNA 
samples (that are present in the membrane in the first staining) were almost completely lost. This fact 
explains the lack of signal in the RNA positive sample and possibly in T. brucei samples. In DNA 
samples the intensity of the staining is lower than the methylene blue staining before the development. 
Therefore, DNA samples were also lost during the development but not completely.  
Due to the inefficient binding of nucleic acids to the membrane, this experiment was 
inconclusive and thus it was not possible to determine if T. brucei nucleic acids harbor m6A. I repeated 
this experiment several times by changing different parameters. First, I tried to improve the binding 
efficiency by cross-linking the membrane by UV exposure. UV cross-linking was performed with the 
auto crosslink default parameters in Stratalinker® UV Crosslinker (254 nm; 120 milijoules/cm2). I tried 
to use a different parameter to UV crosslink (254 nm; 70 milijoules/cm2), which is indicated in the 
membrane manual as optimal for the membrane. Additionally I tried another apparatus (uvitec UV 
crosslinker CL-E508) with the same parameters (254 nm, 120 milijoules/cm2). The result was identical 
to described above. Another possibility was that the membrane was not in the proper conditions, so I 
tried a new membrane (identical to the old, but opened recently), however the result was identical. 
Because the loss of sample is much more pronounced in RNA samples, one possible problem, at least 
in RNA samples, could be the presence of RNases contamination in the development buffers, even 
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though the use of RNase free water to make the buffers. I replace all buffers to new ones, and 
supplement with RNaseOUT (10 U/mL in all buffers and 40 U/mL in the antibody solution). New 
buffers and the supplement with RNaseOUT did not prevent the loss of RNA from the membrane. 
Detection of m6A in T. brucei nucleic acid samples with immunoblot method failed. The 
method needs to be optimized, it is necessary to solve these problems to allow the detection with the 
immunoblot technique.   
  
3.2. Detection and quantification of m6A in T. brucei (in 
bloodstream and procyclic forms)  
 
To test if T. brucei has the m6A modification in DNA or RNA I next tried an alternative 
approach: a commercially available kit, EpiQuik™ m6A RNA Methylation Quantification Kit. Briefly, 
the kit consists in an ELISA-like assay in which nucleic acids are bound to the wells and incubated 
with an anti-m6A antibody. After washing to remove unbound antibody, it is incubated with a 
secondary antibody. The quantification is achieved through incubation with substrate that generates a 
blue color product. The intensity of the color generated is measured in a plate reader. The intensity of 
the color is proportional to the amount of m6A in each well. The kit allows quantitative measurements 
through comparison of the samples intensity with a standard curve, or alternatively only a semi-
quantitative detection, comparing the intensity of the sample with one positive control. The kit 
provides a negative and a positive control, which consists of synthetic oligos without or with m6A, 
respectively. As for the immunoblot assay, I used controls from biological samples: mouse liver RNA 
(C57BL/6 mouse) and E. coli (JM109 strain, Dam+). T. brucei samples consisted of total RNA 
(DNaseI treated) and DNA (RNase A treated), both from bloodstream and procyclic forms.  
In the first preliminary experiment I tested if m6A was present in the two types of nucleic acids 
(RNA and gDNA) from the two life-cycle stages (bloodstream and procyclic forms). Signals generated 
in the four T. brucei samples had an intensity that was double or more than the negative control (Table 
3.2.). Because in this preliminary assay, the intensity of each sample was compared to only one 
positive control, and not to a standard curve, the calculation of m6A/A (%) (fifth column of table 3.2.) 
is a semi-quantitative estimate.   
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Table 3.2. Detection of m6A in RNA and DNA samples. OD represents optical density, NC represents negative control. 
SAMPLE LIFE STAGE OD 
OD – NC 
OD 
M6A/A (%) 
Negative control - 0,069 0 0 
Positive control - 1,155 1,086 100 
T. brucei RNA Bloodstream 0,186 0,117 0,22 
T. brucei DNA Bloodstream 0,136 0,067 0,12 
T. brucei RNA Procyclic 0,271 0,202 0,37 
T. brucei DNA Procyclic 0,195 0,126 0,23 
Mouse liver RNA - 0,440 0,371 0,684 
E. coli DNA - 0,572 0,503 0,926 
 
 This data provides the first evidence that m6A modification exists in RNA and DNA from T. 
brucei. Together, with the spliced leader cap modifications (Bangs et al., 1992; Zamudio et al., 2009) 
and the 5-methylcytosine in tRNA (Militello et al., 2014), m6A constitutes a novel modification of the 
epitranscriptome of T. brucei. It has been previously shown that DNA in T.brucei contains 5-
methylcytosine (Militello et al., 2008) and base J (Gommers-ampt et al., 1993). Here, I present the first 
evidence of m6A as a new DNA modification in T. brucei DNA. This is in agreement with a previous 
study suggesting that m6A could exist in T. cruzi DNA (Rojas and Galanti, 1990).  
The proposed hypothesis was that the m6A modification in RNA was associated with the 
regulation of gene expression at post-transcriptional level, therefore in the remainder of my thesis I 
focused on the modification in RNA. Future studies will characterize this modification in DNA. 
I tested if the levels of m6A were identical in two different stages of the life cycle, the 
mammalian bloodstream form and the insect procyclic form, measuring the levels in RNA and 
compared to a standard curve.  In bloodstream form the m6A levels are 0,34% (±0,07%) and in 
procyclic RNA are 0,51% (±0,24%), relative to total adenosines.  Although there is a tendency for 
RNA from procyclic to have higher values of m6A modification, the differences were not statistically 
different (p= 0,400, Mann-Whitney U test) (Figure 3.2.), perhaps because the number of biological 
replicates is only three.  
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 Figure 3.2. Levels of m6A in total RNA from T. brucei AnTat 1.1 SMOx in bloodstream and procyclic forms. Measurements 
result from three independent biological replicates. The data are presented as percentage of m6A relative to total A in 
RNA. 
 
To test if the signals generated are specific to RNA molecules and not other component of the 
sample, for example DNA contamination, RNA samples were treated with RNase A and purified over 
a column (to remove small RNA fragments from RNase A digestion). If the signal in the sample is 
RNA specific it should disappear after RNase treatment. If is due to other component of the sample 
(and is not lost in the purification) the signal should remain. After treatment and purification of one 
RNA sample from bloodstream form and another from procyclic form, the signals were almost 
completely lost. RNAse-treated bloodstream RNA generated a signal of 0,04% (m6A/A) and the 
procyclic to 0,06% (m6A/A), around tenfold less intense than the original samples. With this 
experiment, I conclude that the signal I detect with the anti-m6A antibody in RNA sample is indeed a 
result from a modification of the RNA, and not of a contaminant.  
 
3.3. Levels of m6A during differentiation  
 
Between bloodstream and procyclic form, 33% of the transcripts are differentially regulated 
(Nilsson et al., 2010) and they seem to be regulated in regulons, clusters of transcripts with the same 
expression pattern, during differentiation (Queiroz et al., 2009). I hypothesized that the m6A pattern 
could change during differentiation as a mechanism to regulate the transcript levels. 
Differentiation from bloodstream form to procyclic form in vitro is a fair approximation of the 
natural process that occurs in vivo. This process can be induced by adding cis-aconitate to the medium 
and lowering the temperature to 27ºC (Czichos J, Nonnengaesser C, 1986). Using this methodology, 
the levels of m6A were quantified at different time points throughout differentiation (figure 3.4.).  
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Efficiency of the differentiation was controlled by the expression of procyclin, through flow cytometry 
(figure 3.3.), evaluated 72 hours after induction of differentiation. Negative control correspond to a 
bloodstream culture and positive control correspond to a previously established procyclic culture. As 
expected, procyclin staining signal is negative in bloodstream forms and positive in procyclic forms. 
Considering the intensities of these controls, a threshold to analyze the differentiated culture was 
defined, where quadrant four defines the negative cells and quadrant three the positive cells. Parasites 
obtained 72 hr after initiating the differentiation protocol were also subjected to procyclin staining. 
93.3% of cells showed positive procyclin staining, indicating that the differentiation protocol worked 
well.  
 
 Figure 3.4. Levels of m6A in total RNA during in vitro differentiation of AnTat 1.1 SMOx, from bloodstream form to 
procyclic form. Bloodstream levels and procyclic levels from three independent biological replicates, and differentiation 
time points result from one experiment.  
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Figure 3.3. Cells were stained with FITC conjugated anti-procyclin antibody and analyzed by flow cytometry. Intensity 
of procyclin is represented in horizontal axis. The proportion of cells in each quadrant (Q) is indicated as a percentage 
of total events analyzed. Q4 is considered negative population and Q3 positive population. 
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When m6A levels were quantified at different time points of differentiation, I observed that 
within the first 12 hours of differentiation, m6A levels remain relatively constant and similar to 
bloodstream form (~0.3%). At 24hr, I observed a sharp increase in m6A levels to around 0.7% and the 
levels remained until the end of the experiment at 72hr. To generate more robust evidence, the 
experiment needs to be repeated.  
 
3.4. Levels of m6A in density stress condition    
 
T.brucei response to stress conditions involves changes in gene expression, and evidence 
reveals that this parasite is able to sense and respond to cell density (de Nadal et al., 2011; Reuner et 
al., 1997). Considering this evidence, I hypothesize the involvement of m6A in this specific response. 
This involvement can be determined through an alteration in the levels of m6A in RNA with different 
cell densities. For this purpose, T.brucei parasites were cultivated at the typical density (0,5×106 
cells/mL) and in higher densities (1,5×106 cells/mL and 3,5×106 cells/mL) and the m6A levels 
quantified in total RNA of these cultures (figure 3.5.). 
 
 
Figure 3.5. Levels of m6A in total RNA of T. brucei bloodstream form from cultures with different cell densities. Result 
from one single experiment. 
 
This preliminary test shows that the levels of m6A in total RNA are proportional to cell 
density. Further measurements should be made to give more robustness and confidence. 
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3.5. Characterization of putative m6A methyltransferase and 
demethylases enzymes 
 
The presence of m6A in the RNA of T.brucei, indicates that its genome should encode 
enzymes responsible for RNA adenosine methylation (m6A methyltransferase) and demethylation 
processes (m6A demethylase). In order to identify candidate enzymes, an in silico approach was used. 
After identification of putative genes, knock out cell lines were generated and the m6A levels in these 
cell lines were measured. 
 
3.5.1. Identification of putative RNA m6A methyltransferase  
 
In other eukaryotes, RNA m6A methyltransferases belong to the MT-A70 protein family 
(Bujnicki et al., 2002) . I hypothesized that the T. brucei putative m6A methyltransferases could be a 
homologue of MT-A70 protein-encoding genes. To identify putative candidates, I first used the 
BLAST tool (Basic Local Alignment Search Tool), a method to compare a query sequence to a 
database and find similar sequences there (Altschul et al., 1990, 1997) in TriTrypDB (Database of 
kinetoplastid parasites genomic information, in which several genomic and functional data sets are 
available (Aslett et al., 2010)). As a first query, I blasted the amino acid sequence of several RNA m6A 
methyltransferases from different species (H. sapiens, M. musculus, A. thaliana, D. melanogaster and 
S. cerevisiae). However, this query did not retrieve any significant hits (arbitrary defined as a hit with 
e-value less than 1.E-3, e-value correspond to the expected number of sequences with an alignment 
score identical or bigger than the hit by chance). Due to the modular evolution of proteins, analysis of 
proteins domains as discrete units (Bhattacharyya et al., 2006; Moore et al., 2008) combined with the 
application of Hidden Markov Models (HMM), could be more sensitive than BLAST (Eddy, 2011; 
Madera and Gough, 2002). Pfam database applies this method to organize proteins domains into 
families (Finn et al., 2014). However, according to this database, MT-A70 family (PF05063) does not 
have any T.brucei protein annotated. 
The MT-A70 protein family is very similar to the family of the prokaryotic DNA m6A 
methyltransferases. Both possess the Rossman fold domain and similar conserved motifs, despite the 
order of the motifs being different due to sequence circular permutation (Bujnicki et al., 2002; Malone 
et al., 1995). I hypothesized that genes containing domains typical of DNA m6A methyltransferases, 
could be putative RNA m6A methyltransferases. 
However, neither BLAST in TriTrypDB nor Pfam searches with representative sequences of 
the three classes of DNA m6A methyltransferases (Dam α group, M.RsrI β group and M.TaqI ϒ group 
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(Malone. 1996)) lead to the identification of putative sequences in T.brucei. The lack of similar 
candidates detectable by BLAST and HMM searches could be the result of a highly divergent 
evolution of this species. Alternatively, the methyltransferase reaction in T. brucei may be catalyzed 
by divergent enzymes. 
As previously described, the sequences of RNA and DNA m6A methyltransferases have a set 
of relatively conserved motifs, among which one of the most conserved is called motif IV (Bujnicki et 
al., 2002; Malone et al., 1995) .This motif interacts directly with N6 (the - nitrogen atom in m6A) 
promoting the  transfer of the methyl group (Goedecke et al., 2001). Therefore I search for this motif 
as an alternative strategy to find putative m6A methyltransferases genes. The Prosite database has a 
description of patterns/motifs in proteins families (Hulo et al., 2006), where it is possible to find the 
motif IV pattern (PS00092) described with the [LIVMAC]-[LIVFYWA]-{DYP}-[DN]-P-P-[FYW] 
regular expression, and annotated as “N-6 Adenine-specific DNA methylases signature”. In 
TriTrypDB, the gene Tb927.7.6620 has this regular expression in the form of VVADPPF, and it is 
annotated as “hypothetical protein, conserved”. This protein has a domain annotated as “Probable N6-
adenine methyltransferase” (PF10237, e-value of 9.E-37), due to the presence of the conserved motif IV 
in this family. This family is distinct from the MT-A70, MethyltransfD12, N6_N4_Mtase, and 
Methyltransf_26 families, which contain the described RNA and DNA m6A methyltransferases. 
However, these five families are grouped in the same Pfam clan (CL0063).  
I next aligned the sequence of Tb927.7.6620 to other members of its family (Pfam PF10237 
family) using Clustal Omega algorithm (Sievers et al., 2011) and predicted the secondary structure 
with Jpred (Cole et al., 2008) and Psipred (McGuffin et al., 2000) algorithms. Conserved regions are 
observed in the multiple sequence alignment (MSA) where, as expected, motif IV was identified. 
However, identification of other motifs was not so obvious, due to the low sequence conservation 
within the motifs (figure 3.6.). The predicted secondary structure of Tb927.7.6620 corresponds to the 
Rossmann fold domain, due to the β-α-β repeats observed (Michael G. Rossmann, 1974), this 
structural domain is found in m6A methyltransferases (Bujnicki et al., 2002; Malone et al., 1995). 
Overall, the in silico analysis have allowed me to identify one putative gene, Tb927.7.6620, 
that may encode for the RNA m6A methyltransferase. 
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3.5.2. Identification of putative RNA m6A demethylases 
 
To identify putative m6A demethylases, a similar in silico strategy was adopted. The enzymes 
known to catalyze this reaction in other eukaryotes are FTO (Jia et al., 2011) and ALKBH5 (Zheng et 
al., 2013a) . The search for sequences similar to FTO, through BLAST in TriTrypDB and domains in 
Pfam did not lead to any significant hit. However, blasting ALKBH5 as a query in TriTrypDB 
retrieved one significant hit: Tb927.5.980 (e-value of 4E-05), annotated as “hypothetical protein, 
conserved”. This gene encodes a protein that contain a domain from the “2OG-Fe(II) oxygenase 
superfamily” (PF13532). This family includes the RNA m6A demethylase ALKBH5, the remaining 
human ALKBH proteins and the E.coli AlkB. This protein (AlkB) repairs DNA through 
demethylation of damaged bases (Falnes and Rognes, 2003) and was the base to find the human 
ALKBH (1-8) (AlkB homologs) group (Kurowski et al., 2003) . After performing a search for proteins 
Figure 3.6. Multiple sequence alignment of sequences of the putative N6-adenine methyltransferase family; 
Conserved motif IV is marked above the corresponding amino acids; in the secondary structure prediction H 
represents α-helix and E represents β-strand. Numbers in parentheses are positions not represented. Numbers at the 
beginning and end represent the start and end positions of each sequence on the MSA. 
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containing this domain in T. brucei, five additional proteins were detected with a significant e-value 
(table 3.3.). 
Table 3.3. T. brucei proteins with 2OG-Fe(II) oxygenase domain, putative T. brucei alkB homologs 
TRITRYPDB ID UNIPROT ID 
PFAM 
E-VALUE 
TRITRYPDB ANNOTATION 
ATTRIBUTED 
NAME 
 
Tb927.4.460 Q57US9 5.6e-54 Alkylated DNA repair protein TbALKBH1  
Tb927.5.980 Q57W43 4.0e-13 hypothetical , conserved TbALKBH2  
Tb927.7.1530 Q57WP7 1.4e-12 hypothetical , conserved TbALKBH3  
Tb927.10.6450 Q38AW1 1.9e-08 hypothetical , conserved TbALKBH4  
Tb927.11.10960 Q383I2 2.1e-08 hypothetical , conserved TbALKBH5  
Tb927.11.11390 Q383D9 6.8e-08 hypothetical , conserved TbALKBH6  
 
 
 
Considering the candidates on table 3.3., only Tb927.4.460 has a functional annotation as 
“Alkylated DNA repair protein (alkB homolog), putative”. This protein was shown to partially 
complement AlkB knockout in E. coli, under DNA damage stress conditions, indicating that it could 
be a functional AlkB protein. However, evidence regarding the substrate and biochemical function in 
T. brucei has not been addressed (Simmons et al., 2012).  
A MSA of these T. brucei proteins with AlkB and human ALKBH (1-8) revealed the 
conservation of critical residues on the candidate proteins (Figure 3.7.). These residues are the 
homologues to positions His131, Asp133, His187, Arg204 and Arg210 in E. coli AlkB. The presence 
of this domain with the conserved residues suggests these are T. brucei AlkB homologs (TbALKBH 1-
6). 
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 Figure 3.7. Multiple sequence alignment of sequences of the E. coli alkB, Human ALKBH and possible TbALKBH; 
conserved positions are marked with #; Numbers in parentheses are positions not represented. Numbers at the 
beginning and end represent the start and end positions of each sequence on the MSA. Columns with spaces inside 
parentheses denotes regions of the MSA not represented.  
 
Similarly to ALKBH5 in H. sapiens where only one out of the eight ALKBH proteins is an 
RNA m6A demethylase, it is possible that within that putative T. brucei AlkB homolog group are RNA 
m6A demethylase enzymes. To test this possibility, the two best candidate genes were selected to 
generate the knockout (KO) cell lines: Tb927.5.980 and Tb927.4.460. Additionally in one candidate 
(TbALKBH1) was presented evidence that this is an AlkB protein  (Simmons et al., 2012). 
  
In summary, informatic analysis of T. brucei genome based on conserved sequence features 
lead me to identify one putative m6A methyltransferase and five m6A demethylases. In the next 
section, KO cell-lines were generated for the putative m6A methyltransfrease gene (Tb927.7.6620) and 
for the two best candidate genes encoding for m6A demethylases (Tb927.5.980 and Tb927.4.460). 
 
 
 
 
38 
 
3.5.3. Generation of knockout cell lines of putative enzymes   
 
To test if the putative enzymes described above are indeed m6A methyltransferase or 
demethylases, I decided to generate knockout parasite lines, so that I can genetically address the 
function of the genes. Generation of knockout cell lines consists in removing both alleles of the 
putative gene, usually by replacement with a drug resistance gene. Thus, my first task was to generate 
a construct that contained a drug selectable marker flanked by sequences that allow recombination in 
the genome and subsequent deletion of the targeted allele (Fig 3.8A). The untranslated regions (UTRs) 
of the drug resistance genes were either from the Aldolase or Actin genes. The endogenous UTRs of 
the targeted genes may have non-annotated regulatory elements that destabilize the transcripts and 
could, as a result, reduce the expression of the resistance genes. To avoid this possible effect, our 
constructs were designed to delete not only the targeted gene, but also their UTRs. 
 
 
 Figure 3.8. A- Strategy to replace the putative genes by the resistance gene via double recombination; B- Locus in the KO 
cell lines after the replacement of the two alleles; REC- Recombination region, UTR- untranslated region. Endogenous 
UTRs are in green, exogenous UTRs in orange; aldolase UTRs in purple and actin UTRs in yellow; NEO- G410; HYG-
Hygromycin. 
 
For each candidate gene, two vectors were made, each with a different selectable marker 
(NEO or HYG) (table 3.4.) to replace the two wild type alleles (figure 3.8B) 
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 Table 3.4. Vectors designed to KO the candidate genes. 
PUTATIVE 
 FUNCTION 
TARGET 
GENE 
VECTOR 
RESISTANCE 
GENE 
CELL 
LINE 
DESCRIPTION 
RNA m6A  
demethylase 
Tb927.5.980 
pIV1 NEO IV1 KO of first allele 
pIV2 HYG IV2 KO of second allele 
RNA m6A  
demethylase 
Tb927.4.460 
pIV3 NEO IV3 KO of first allele 
pIV4 HYG IV4 KO of second allele 
RNA m6A 
methyltransferase 
Tb927.7.6620 
pIV5 NEO IV5 KO of first allele 
pIV6 HYG IV6 KO of second allele 
 
 
The fragments to generate the constructs were obtained by PCR amplification and are 
described in table 3.5. and Figure 3.9. 
 
 
Table 3.5. Inserts to generate the pIVs vectors.   
PCR 
PRODUCT 
TARGET GENE DESCRIPTION VECTOR 
EXPECTED 
SIZE (BP) 
1 Tb927.5.980 5’ recombination region to ligate with NEO pIV1 230 
2 Tb927.5.980 3’ recombination region to ligate with NEO pIV1 301 
3 Tb927.5.980 5’ recombination region to ligate with HYG pIV2 230 
4 Tb927.5.980 3’ recombination region to ligate with HYG pIV2 301 
5 Tb927.4.460 5’ recombination region to ligate with NEO pIV3 361 
6 Tb927.4.460 3’ recombination region to ligate with NEO pIV3 324 
7 Tb927.4.460 5’ recombination region to ligate with HYG pIV4 361 
8 Tb927.4.460 3’ recombination region to ligate with HYG pIV4 324 
9 Tb927.7.6620 5’ recombination region to ligate with NEO pIV5 452 
10 Tb927.7.6620 3’ recombination region to ligate with NEO pIV5 521 
11 Tb927.7.6620 5’ recombination region to ligate with HYG pIV6 452 
12 Tb927.7.6620 3’ recombination region to ligate with HYG pIV6 521 
13 --- NEO gene pIV(1,3,5) 1176 
14 --- HYG gene pIV(2,4,6) 1445 
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All purified DNA fragments showed the expected molecular masses. The backbone for my 
constructs, which contains the ampicillin resistance gene and the E. coli origin of replication, was 
obtain by digestion of pFAB2, a plasmid previously available in the laboratory. Upon transformation 
of the reaction products in E. coli, colonies were tested for the presence of the desired plasmids by 
digesting plasmid DNA with restriction enzymes (table 3.6., Figure 3.10.). 
 
Table 3.6. Restriction digestions to confirm the cloned plasmids. 
DIGESTION  
PRODUCT 
VECTOR 
RESTRICTION ENZYMES  EXPECTED  
PRODUCTS (BP) 
1 pIV1 EcoRI + KpnI 3022 + 1501 
2 pIV2 BamHI + SacI 2870 + 1922 
3 pIV3 BsaI + KpnI 3166 + 1511 
4 pIV4 EcoRI + NotI 3534 + 1368 
5 pIV5 BamHI + KpnI 3570 + 1395 
6 pIV6 EcoRI + NotI 3669 + 1565 
 
 
 
 
 
 
 
Figure 3.9. Agarose gel of the inserts amplifications products after gel extraction, lane M: marker 1 Kb ladder; lanes 1 to 
14 correspond to PCR products in table 3.5. Ladder size is marked in bp.  
Figure 3.10. Agarose gel of the vectors digestion. Lane M: marker 1Kb ladder; lanes 1 to 6 correspond to digestion 
products of table 3.6. Ladder size is marked in bp. 
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The extracted plasmids exhibit the expected digestion pattern as shown in table 3.6. and Figure 
3.10. Therefore, those should be the desired plasmids. After these preliminary digestion patterns, 
sequencing confirmed that all constructs have the expected sequences and are therefore ready for 
transfection in T. brucei. 
The knockout mutants were generated in a pleomorphic strain of T. brucei: AnTat1.1E. A 
modified version of this strain, SMOx, contains the T7 polymerase and TET repressor. These elements 
are not critical to produce the KO cell line, but they may be useful in future studies to inducibly 
complementing the phenotype, for example. Therefore, I chose to transfect the KO constructs into 
SMOx. 
SMOx was first transfected with constructs to replace the first allele (pIV1, pIV3 and pIV5 
independently) and the clones were selected with G418. G418-resistant clones were genotyped to 
confirm the correct integration. Two amplifications were performed: one amplification in which the 
primers hybridize upstream of the 5’ recombination region and inside the construct and another 
amplification in which the primers hybridize inside the construct and downstream of the 3’ 
recombination regions (primers table annexes). I observed that on average 4/5 clones showed the 
correct integration. The clones that exhibit the correct integration correspond to the cell lines IV1, IV3 
and IV5. These clones were subsequently used to transfect the second construct (pIV2, pIV4 and 
pIV6) to replace the second allele. Hygromycin-resistant clones were generated and called IV2, IV4 
and IV6. Two clones were obtained for each KO cell line in which the genotyping results confirmed to 
be the desired cell line (tables 3.7., 3.8. and 3.9., Figures 3.11., 3.12. and 3.13.). Genotyping results 
with the two amplifications described above, for each resistance gene, reveal that in the three knockout 
cell lines resistance genes recombined in the right locus, replacing the gene of interest.  
 
Table 3.7. Amplifications to genotype resistance genes integration in Tb927.5.980 locus. 
 
 
 
 
 
 
 
 
SUBSTRATE INTEGRATION 
EXPECTED 
 SIZE (BP) 
PCR  
PRODUCT 
 AnTat 5’ NEO --- 1 
IV2 5’ NEO 1406 2 
AnTat 3’ NEO --- 3 
IV2 3’ NEO 839 4 
AnTat 5’ HYG --- 5 
IV2 5’ HYG 1614 6 
AnTat 3’ HYG --- 7 
IV2 3’ HYG 759 8 
Figure 3.11. Agarose gel of resistance genes integration regions amplification. Lanes: M-marker 1 Kb ladder, lanes 1 to 8 
correspond to PCR products in table 3.7. Ladder size is marker in bp.  
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Table 3.8. Amplifications to genotype resistance genes integration in Tb927.4.460 locus. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.9. Amplifications to genotype resistance genes integration Tb927.7.6620 locus. 
 
 
 
 
 
 
 
 
 
Besides amplification of recombination regions, the locus was amplified (the three loci), the 
different size of each allele (wild type, G418 and Hygromycin) allows to distinguish each other (with 
the exception of Tb927.5.980 and G418, in which the difference in size is not distinguishable in 
agarose gel) (Table 3.10. and Figure 3.14.). In all three loci, amplification in AnTat 1.1 SMOx 
generates the expected molecular size product. After removal of the first allele, of the three candidates, 
through replacement with G418 gene (intermediate cell lines only with one allele removed, IV1, IV3 
SUBSTRATE INTEGRATION 
EXPECTED 
 SIZE (BP) 
PCR  
PRODUCT 
 AnTat 5’ NEO --- 1 
IV4 5’ NEO 1347 2 
AnTat 3’ NEO --- 3 
IV4 3’ NEO 841 4 
AnTat 5’ HYG --- 5 
IV4 5’ HYG 1555 6 
AnTat 3’ HYG --- 7 
IV4 3’ HYG 763 8 
SUBSTRATE INTEGRATION 
EXPECTED 
 SIZE (BP) 
PCR  
PRODUCT 
 AnTat 5’ NEO --- 1 
IV6 5’ NEO 1807 2 
AnTat 3’ NEO --- 3 
IV6 3’ NEO 1095 4 
AnTat 5’ HYG --- 5 
IV6 5’ HYG 2015 6 
AnTat 5’ HYG --- 7 
IV6 5’ HYG 1015 8 
Figure 3.12. Agarose gel of resistance genes integration regions amplification. Lanes: M-marker 1 Kb ladder, lanes 1 to 8 
correspond to PCR products in table 3.8. Ladder size is marker in bp.  
Figure 3.13 Agarose gel of resistance genes integration regions amplification. Lanes: M-marker 1 Kb ladder, lanes 1 to 8 
correspond to PCR products in table 3.9. Ladder size is marker in bp. 
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and IV5), amplification of the locus reveals an additional band that correspond to G418. In the double 
knockout cells, the amplification reveals the presence of the two alleles (G418 and hygromycin) 
instead of wild type allele.  
 
Table 3.10. Amplifications of the three candidate genes locus 
LOCUS ALLELE 
EXPECTED 
SIZE (BP) 
PCR 
PRODUCT 
Tb927.5.980 
WT 2001 1 
NEO 2085 2 
HYG 2354 3 
Tb927.4.460 
WT 2853 4 
NEO 2030 5 
HYG 2299 6 
Tb927.7.6620 
WT 4052 7 
NEO 2742 8 
HYG 3011 9 
 
 
 
 
 
 
 
 
 
Figure 3.14. Agarose gel showing genotyping of single and double-knockout cell lines of the three putative gene loci A) 
Tb927.5.980 B) Tb927.4.460 and C) Tb927.7.6620 locus.  Lanes: M- marker 1 Kb ladder, lanes 1 to 9 correspond to PCR 
products in table 3.10. Ladder size is marker in bp 
 
Amplification of integration regions reveals that the resistance genes integrated in the 
expected locus, in the three selected candidates. Accordingly, amplification of the locus revealed 
products with sizes corresponding to the two resistance genes. These data demonstrate that the clones 
obtained are knockouts of the target genes.  
Obtaining knockout cells indicates that the genes (three candidates) are not essential. In 
knockout of Tb927.5.980 gene, putative demethylase TbALKBH2, a reduction on growth rate was 
observed (figure 3.15A): relative to parental cell-line, which has a doubling time of 7:05hr, two clones 
A B C 
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showed doubling times of 9:19hr and 8:51hr. In the other knockout cell line of Tb927.4.460 gene 
(putative demethylase TbALKBH1), a reduction in growth rate was also observed (figure 3.15B), the 
doubling time of which is longer in the two clones (10:13hr for clone1 and 9:17hr for clone 2). The 
knockout cell line of the putative methyltransferase gene, Tb927.7.6620, showed only a minor effect 
in the growth rate in the two clones (7:36 h for clone 1 and 7:09 h for clone 2) (figure 3.15C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B A 
C 
Figure 3.15. Growth curve of knockout cell lines during 8 days of culture. A) IV2 cell line (Tb927.5.980 putative RNA 
m6A demethylase) B) IV4 cell line (Tb927.4.460 putative RNA m6A demethylase) C) IV6 cell line (Tb927.7.6620 
putative RNA m6A methyltransferase). Result from one single experiment with the two obtained clones of each 
candidate.  
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3.5.4. Measurement of m6A levels in knockout cell lines 
 
To test if the three selected candidate proteins are involved in m6A modification, I measured 
the levels of m6A on the KO cell-lines. I expected the lack of the methyltransferase to result in a 
reduction of the m6A levels, while the lack of the demethylase should result in an increase of m6A 
levels. The levels of m6A were measured in total RNA from the KO cell lines (figure 3.16.). The levels 
in one demethylase candidate (Tb927.5.980, IV2 cell line) cell line seems slightly higher than parental 
cell line (AnTat 1.1 SMOx), however the number of biological replicates does not allow to establish 
statistical support of this increase. A small increase in m6A levels (9%) have also been observed in 
ALKBH5 mutants (Zheng et al., 2013a) . The KO of the other demethylase candidate (Tb927.4.460, 
IV4 cell line) does not change the levels of m6A relative to the parental cell line. This result might 
suggest that one candidate (Tb927.5.980) could be a RNA m6A demethylase, whilst the second 
candidate (Tb927.4.460) does not.  
In contrast to what I expected, m6A levels did not decrease in the KO cell-line of the putative 
methyltransferase gene (Tb927.7.6620, IV6 cell line), therefore this candidate does not seem to be an 
RNA m6A methyltransferase.  
 The same analysis was done in procyclic forms, a different stage of T. brucei life 
cycle. For this, I differentiated one clone of each of three knockout cell-lines using the protocol 
described earlier. In procyclic, I did not detect any alteration in the m6A levels between any of the cell-
lines.  
 I obtained no evidence to prove that the three putative genes are indeed m6A 
methyltransferases or demethylases. As discussed later in this thesis, there are several scenarios that 
could justify that the levels m6A remain unchanged, even if the enzymes are truly involved in m6A 
metabolism. 
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Figure 3.16. Levels of m6A in total RNA in the generated KO cell lines, A) in bloodstream form and B) procyclic form. IV2 
and IV4 are the knockout of the two RNA m6A demethylase candidates (Tb927.5.980 and Tb927.4.460) and IV6 a 
knockout of RNA m6A methyltransferase candidate (Tb927.7.6620). In the three case clone 1 was used. AnTat 
measurements result from 3 independent experiments. Knockout bloodstream forms measurements result from two 
independent experiments and knockout procyclic measurements from one single experiment.  
 
Overall, my study suggests that one of the three putative genes (Tb927.5.980) might be an 
m6A demethylase, while the other two might not have a role in the m6A modification process. 
However, due to the small sample size and the possible small changes associated with the knockout of 
published orthologs, other assays would be necessary to further validate my observations. 
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4. Discussion 
 
4.1. N6-methyladenosine (m6A) in RNA of T. brucei  
 
In several eukaryotes m6A in RNA has been associated with post-transcriptional gene 
regulation, through diverse molecular mechanisms and possibly affecting mRNA metabolism in 
diverse steps (Fu et al., 2014; Meyer and Jaffrey, 2014) . T. brucei gene expression regulation occurs 
mainly at post-transcriptional level (Clayton, 2002). Therefore in this thesis I proposed that m6A in 
RNA could be a novel mechanism of gene regulation in this parasite.  
In this study, I identified m6A modification for the first time in T. brucei RNA. I detected this 
modification in the two different life-cycle stages: bloodstream slender form and procyclic form. 
Levels of m6A in RNA relative to the total number of adenines is around 0,3% in bloodstream form 
and around 0,5% in procyclic form.  These levels are in the same order of magnitude as in other 
eukaryotes:  0,1%-0,4% in mRNA in human cells (Perry and Kelley, 1975), 0,25% in S. cerevisiae  
(Bodi et al., 2010) and 1,5% in A. thaliana (Zhong et al., 2008). Although the levels between these 
two life-cycle stages are very similar, it does not mean that the targets are the same, neither the 
stoichiometry within the targets. It is plausible that in different life stages, the methylation targets are 
different, and/or in the same transcript population, the stoichiometry varies for developmental 
regulation purposes.  
T. brucei is an eukaryote that exhibits features that are distinct from canonical eukaryotes, 
including polycistronic gene organization (Berriman et al., 2005), RNA maturation by trans-splicing 
(Liang et al., 2003) and lack of mRNA transcriptional control (Clayton, 2002). These distinctive 
features could be explained due to the fact that T. brucei speciation occurred early in the eukaryotic 
lineage (Douzery et al., 2004). Nevertheless, it is possible that some m6A molecular mechanisms and 
functions observed in other eukaryotes are conserved in T. brucei. For example, RNA Recognition 
Motifs (RRM) are present in several T. brucei proteins (Clayton, 2013) and they have been associated 
to the stabilization of mRNAs (Wang et al., 2014b). Expression of human HuR protein (an RRM-
containing protein) in T.brucei leads to stabilization of some mRNAs, through binding to ARE (AU-
rich element) containing transcripts (Quijada et al., 2002). These observations suggest that possibly, 
this mechanism of mRNA stabilization through HuR binding could be conserved in T. brucei. 
 In the eukaryotic lineage, m6A modification is found in rRNA, snRNA and in mRNA (Cantara 
et al., 2011). In T. brucei, I detected m6A levels in total RNA, which means that all methylated 
transcripts were quantified. With our assay, it was not possible to discriminate in which types of RNA 
this modification is present. An immunoblot after RNA separation is a complementary approach, 
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which would tell me the size of the molecules that are methylated. Definitive identification of the 
targets would require more sophisticated methods involving immunoprecipitation and RNA 
sequencing (meRIP-seq). The possible presence of m6A in the mRNA of T. brucei is more promising 
in the context of the hypothesis that m6A is involved in T. brucei post-transcriptional gene regulation. 
Nevertheless, if this modification is only present on other types of RNAs it may also be interesting, 
since the function of this modification in other RNAs is unknown.  
 
To understand the function of this modification, it is important not only to discriminate which 
types of RNAs contain m6A, but also to localize the methylated nucleotides in the transcripts. This 
localization could indicate possible functions and reveal putative methylation motifs, which could be 
empirically tested after, for example through mutational analysis. Also, with the methylated 
transcriptome revealed, it will be possible, for example, to select a set of methylated transcripts and a 
set of non-methylated transcripts to compare different properties, like the kinetics of decay using 
transcription inhibitors, knockout cell lines (of the enzymes involved in the methylation process) or 
methylation inhibitors. This strategy may indicate if this modification is important for the stability of 
mRNA transcripts, as it has been previously shown for transcripts that regulate self-renewal ability in 
mouse stem cells (Wang et al., 2014b) . 
Gene ontology analysis of m6A targets may indicate the biochemical pathways and biological 
process potentially regulated by RNA m6A methylation. Comparing methylated transcriptome in 
different life-cycle stages could help us understand if the modification is dynamic, regulated and 
which biological processes are more regulated by m6A in RNA.  
Spliced Leader (SL) cap modifications , namely 7-methylguanosine, 2-O-ribose methylations, 
N6,N6,2'-O-trimethyladenosine, 3,2'-O-dimethyluridine and pseudouridine (Bangs et al., 1992; 
Zamudio et al., 2009) and the presence of 5-methylcytosine in tRNAs (Militello et al., 2014), were, 
until now, the only RNA modifications known in T. brucei. This finding, the presence of m6A in T. 
brucei RNA, adds a new modification to the epitranscriptome.  
 
4.2. N6-methyladenosine (m6A) in DNA of T. brucei  
 
One of the results of this thesis is the identification for the first time of N6-methyladenosine in 
DNA of T. brucei. This novel DNA modification was detected in both life-cycle stages. In every 
10.000 adenines, 12 are N6-methylated in bloodstream. In procyclic the frequency is about the double. 
DNA modifications are epigenetic marks. 5-methylcytosine is one of the best characterized in several 
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eukaryotes and it is well established its role in transcriptional gene regulation (Jones, 2012). In T. 
brucei, two DNA modifications have been previously described: 5-methylcytosine (Militello et al., 
2008) and base J (Gommers-ampt et al., 1993). The function of 5-methylcytosine and base J in T. 
brucei have not been well established, however it seems that base J is involved in regulation of 
transcription termination (Reynolds et al., 2014). In DNA, m6A is found in bacteria, archaea, protists 
and fungi, where besides being part of modification-restriction systems, it is an epigenetic mark 
involved in diverse processes, including chromosome replication, DNA repair, transposition and 
transcription of specific genes (Wion and Casadesús, 2006). Some of these functions could be 
conserved in T. brucei. The levels of 5-methylcytosine in T. brucei are lower than in canonical 
eukaryotes (around 0,01% in T. brucei and around 0, 25%  in human tissues, varying from tissue to 
tissue (Ehrlich et al., 1982) , therefore it is possible that m6A in DNA compensates some functions 
usually associated to m5C. One major function of m5C is the involvement in transcription repression, 
in T. brucei poll II transcription is mainly constitutive and therefore it is not surprising to have reduced 
levels of m5C. Nevertheless, a large part of the genome encodes VSGs in silent state, m5C and m6A 
could be important to repress this loci. 
Because promoters for Pol II in T. brucei lack recognisable sequence elements, a putative 
function of m6A in DNA could be to mark specific genomic loci like, such as transcription start sites 
and transcription termination sites. Chromatin alterations observed in these genomic regions (Siegel et 
al., 2009) could be promoted by the presence of m6A in DNA in these genomic regions. This 
hypothesis could be addressed by mapping the modification in the genome, which could be achieved 
by chromatin immunoprecipitation followed by high throughput sequencing.  
 
4.3. Levels of RNA m6A during differentiation 
 
During T. brucei differentiation, several changes occur in gene expression (Queiroz et al., 
2009). If m6A is involved in gene regulation during differentiation it is possible that the levels of this 
modification are regulated during this process. For example, in S. cerevisiae this modification only 
appears in RNA during meiosis (Clancy et al., 2002).  
In vivo bloodstream slender cells differentiate into non-dividing stumpy cells, leading to a cell-
cycle arrest in G1 phase, in the mammalian host (Fenn and Matthews, 2007). These cells, upon 
transfer to the tsetse in its blood meal, continue the development to the procyclic form while the 
bloodstream slender forms that are uptaken by the tsetse eventually die (Dyer et al., 2013). In vitro 
differentiation starts with induction with cis-aconitate and temperature reduction to 27°C of a 
bloodstream slender form culture. In the first 12 hours of in vitro differentiation, cells are arrested in 
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G1 phase, do not grow and express genes characteristic to stumpy forms (Queiroz et al., 2009). 
Transcriptomic analysis has shown that during in vitro differentiation, after 12 hours several genes 
important for division, including flagella and ribosomal proteins, glycolysis and other energy 
metabolism pathways reach transcript levels comparable to the observed levels in procyclics. Between 
12 hours and 48 hours, the stumpy-like form restart growing and fully differentiate into procyclic 
forms (Queiroz et al., 2009).  
In this work, I assayed differentiation in vitro. The levels of m6A in RNA remained constant 
(around 0,3%) in the first 12 hours, but at 24 hours the levels of m6A had doubled to around 0,7%. 
Levels remained high till 72hr. Therefore, it seems that m6A levels increase when differentiation from 
stumpy-like form to procyclic is triggered. This correlation, between the m6A levels increase and this 
transition suggests that m6A may have a role in differentiation. Extrapolating to differentiation in vivo, 
it is possible that m6A plays an important role in the transition from stumpy to procyclic, unlike the 
transition from bloodstream slender to stumpy. To address this possibility, the measurement of the 
levels of m6A in stumpy forms will be important. Another possible assay is to measure m6A levels in a 
differentiation assay that starts with stumpy cells (rather than bloodstream slender forms). Stumpies 
can be obtained from an infection in mouse. If the hypothesis is correct, the increase in m6A levels in a 
differentiation started with stumpy cells would be observed without an initial lag phase of 12hr. 
During differentiation several transcripts are regulated with the same pattern, forming post-
transcriptional regulons (Queiroz et al., 2009). It is possible that the presence of m6A defines some of 
these co-regulated clusters. With the information of the methylation targets obtained by meRIP-seq, it 
should be possible to compare the methylation status in the transcripts of different regulons. This co-
regulation could be tested using methylation inhibitors. 
  
 
4.4. m6A RNA modification is sensitive to cell density 
 
Cell density is an important factor in T. brucei life-cycle because high cell density triggers the 
differentiation of bloodstream slender forms to stumpy forms (Reuner et al., 1997). I observed a 
gradual increase in m6A levels from 0,4% to 1,5% when cells were cultivated at higher densities (0,5 
×106 cells/mL to 3,5× 106 cells/mL). Is m6A higher because parasites are responding to cell density 
stress or because they initiated differentiation to stumpies? A quorum sensing mechanism is 
responsible for differentiation from bloodstream slender forms to stumpies in vivo, and this process 
can be reproduced in vitro with agar plates (Reuner et al., 1997). However, in liquid medium, keeping 
cultures at high densities does not promote proper differentiation to stumpies but to a poorly 
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characterized stumpy-like status (Queiroz et al., 2009). Our cell-density assay was performed in vitro, 
which means that I did not have stumpies in culture, but I probably had stumpy-like forms. In our 
differentiation assay (also in vitro) I observed constant levels of m6A in the first 12hr, indicating that 
stumpy-like forms have the same levels of m6A as bloodstream slender forms. Therefore, the increase 
in m6A observed upon increasing cell-density is likely due to the stress of being at high concentration, 
rather than a differentiation process to stumpy-like cells. Stress could result from the accumulation of 
metabolites and the reduction of available nutrients in the culture medium. Response to stress 
conditions usually involves alterations in gene expression (de Nadal et al., 2011). Thus, m6A 
regulation may be involved in T. brucei response to stress, in this case high cell density.  
Increase of m6A levels may be involved in the regulation of specific stress response genes. For 
example, response to heat shock in T. brucei involves the regulation of heat shock genes, through the 
binding of an RNA binding protein that stabilizes the transcripts (Droll et al., 2013). If m6A 
destabilizes transcripts, the increase in m6A levels could result in down-regulation of genes usually 
expressed in normal conditions. An alternative effect is an increased transcript stability, promoting an 
up-regulation, for example, of genes involved in stress response. Comparing the up-regulated and 
down-regulated genes in high stress conditions with the methylation status could reveal a relationship 
between m6A and regulation of stress response genes.  
  
4.5. Putative RNA m6A methyltransferase 
 
So far, the only proteins identified as responsible for the catalysis of m6A formation in RNA 
have a domain from MT-A70 family (Bujnicki et al., 2002; Liu et al., 2014). In the T. brucei genome, 
no annotated gene codifies for a protein with such a domain. The enzyme (or enzymes) that catalyse(s) 
the formation of m6A in T. brucei RNA may be from a different family. On the other hand, a possible 
stronger divergent evolution (more substitutions in the sequence) in trypanosomes, could difficult the 
detection of MT-A70 homologues. The candidate I selected belongs to a protein family N6-
adenineMlase (PF10237) annotated as “Probable N6-adenine methyltransferase”, a distinct family 
from MT-A70 family. The hypothesis that this protein could be an RNA m6A is due to the presence of 
a conserved characteristic motif of m6A methyltransferases (called motif IV) (Bujnicki et al., 2002; 
Malone et al., 1995). Although the function of this domain family is not known, according to Pfam it 
is only found in the eukaryote lineage.  
In higher eukaryotes the presence of m6A in DNA has never been detected (Wion and 
Casadesús, 2006), although this domain (N6-adenineMlase, PF10237) is distributed in several higher 
eukaryotes including Homo sapiens, Mus musculus, Drosophila melanogaster and Arabidopsis 
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thaliana. In these organisms, m6A has been identified in RNA, therefore if this family is an m6A 
methyltransferase, RNA is a more plausible substrate than DNA. In this study, the putative function of 
m6A methyltransferase for RNA of the gene Tb927.7.6620 (that has a N6-adenineMlase, PF10237 
domain) was tested, through the measurement of m6A levels in a KO cell line for this candidate. If this 
candidate was indeed an RNA m6A methyltransferase, a decrease in the m6A RNA methylation levels 
was expected in KO cell-lines. The levels of m6A in the KO cells were measured in both bloodstream 
and procyclic forms. In bloodstream forms, instead of a decrease in RNA m6A levels, a small increase 
was observed relative to the parental cell line. However, this may not be an actual increase due the 
small sample size and variability in measurements. In procyclic forms, the levels in the KO and 
parental cell lines are equivalent. However, the measurements are very variable. Therefore, if the 
decrease in procyclic forms was just slight, it might not be observed due to variability in the 
measurements. For example in mouse cells, after knockdown of m6A methyltransferase (MT-A70 and 
Mettl14), a decrease was observed from around 0,15% (m6A/A) to around 0,05% (m6A/A), 
corresponding to a reduction to 1/3 of the normal levels (Wang et al., 2014b). Moreover, in another 
study, after MT-A70 knockdown in human cells the decrease in m6A levels was around 30%, that 
correspond to a decrease from 0,42% (m6A/A) to 0,30 % (m6A/A) (Liu et al., 2014). Because our 
analysis of the KO cell-line was inconclusive, in the future, mass spectroscopy and in vitro 
biochemical assays may allow us to conclude if the putative RNA m6A methyltransferase is real. 
Another approach is to test if this KO can differentiate properly and if levels of m6A are identical to 
wild-type or not. I should also measure m6A levels in this KO cell-line upon stress of high-density and 
test if levels also increase as observed in wild-type. 
 
4.6. Putative RNA m6A demethylases 
 
In other eukaryotes, the RNA demethylases identified so far are FTO (Jia et al., 2011) and 
ALKBH5 (Zheng et al., 2013a). In T. brucei genome there are six genes that encode for proteins with 
a domain from the same family as ALKBH5, the 2OG-Fe(II) oxygenase superfamily. Proteins that 
contains this domain catalyse diverse reactions, usually the oxidation of an organic compost and this 
domain is present, for example in EGL-9 and Prolyl 3-hydroxylase-1 (Aravind and Koonin, 2001). 
EGL-9 response to low oxygen conditions (hipoxia) through hydroxylation of hypoxia-inducible 
factor (HIF) (Shao et al., 2009). Prolyl 3-hydroxylase-1 (P3H1) converts proline to 3-hydroxyproline 
in type I collagen (Hudson and Eyre, 2014). Multiple sequence alignment of T. brucei proteins with 
human ALKBH (1-8) and E. coli AlkB revealed that the most conserved amino acids are also present 
in T. brucei proteins. Due to the sequence similarity and conservation of the critical amino acids, it is 
possible that these proteins could be functional AlkB proteins, and possibly one (or more than one) 
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could be an m6A RNA demethylase. Thus, I termed these six putative proteins as T. brucei AlkB 
homologues (TbALKBH (1-6)).  
In this study, two out of the six identified T. brucei ALKBH proteins (Tb927.4.460 called 
TbALKBH1 and Tb927.5.980 called TbALKBH2) were tested for a putative function of RNA m6A 
demethylase, by measuring RNA m6A levels in KO cell lines. If one of the two proteins is an RNA 
m6A demethylase, I expected an increase in the methylation levels. The levels were measured in both 
life-cycle stages, bloodstream and procyclic form. RNA m6A demethylase candidate knockout, 
Tb927.4.460 (TbALKBH1), showed identical levels of m6A in RNA between parental and KO cell-
lines in both life-cycle stages. Therefore, it seems that this TbALKBH1 is not an RNA m6A 
demethylase. In the bloodstream form of Tb927.5.980 (TbALKBH2) knockout, a slight increase in the 
m6A levels in RNA was observed from 0, 34% to 0, 45%, relative to total adenosines. Therefore this 
protein might be an m6A RNA demethylase. In procyclic form, the m6A levels were identical between 
parental and KO cell-lines, suggesting that there is either a second demethylase or that the change in 
m6A RNA levels is more subtle in procyclic forms.  
Two relevant factors need to be considered when analysing the putative RNA m6A 
demethylase activities in the knockout parasites. First, the fold increase in the levels of m6A in RNA 
expected. For example, Zheng and colleagues only found a “modest” increase (from around 0,50% to 
0,55% (m6A/A)) in m6A levels in cultured cells after knockdown of the human RNA m6A demethylase 
that belongs to the same superfamily of T. brucei candidates (Zheng et al., 2013a). Second, the high 
variability observed in measurements with this method. Together, the high variability combined with 
possible slight increase in the m6A levels can make difficult to evaluate the demethylase activity of the 
candidates. The small sample size does not allow a statistical analysis neither the identification of 
outliers, that may be increasing the variability observed. Measurement of m6A levels in KO cell lines 
with mass spectroscopy and with a bigger sample size may give more robust evidence to determine if 
the candidates are true RNA m6A demethylases. Biochemical assays in vitro (for example, incubation 
of purified candidates with m6A methylated RNA substrate and analyse the products) and 
overexpression (observe if the levels in RNA decrease) can generate supplementary evidence. 
Together, the data so far suggests that one candidate could be an RNA m6A demethylase, which is 
mainly active in bloodstream form (Tb927.5.980). 
 
  
.  
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5. Conclusion 
 
 
 N6-methyladenosine is an RNA modification distributed in the transcriptome of 
eukaryotes and was associated to post-transcriptional gene regulation. This regulation seems to occur 
through diverse molecular mechanisms, affecting diverse steps in the RNA  processing, including 
transport and stability (Fu et al., 2014; Meyer and Jaffrey, 2014). In T. Brucei, gene expression 
regulation occurs mainly at post-transcriptional level (Clayton, 2002). My hypothesis is that this 
modification exists and is a mechanism of gene expression regulation in T. brucei. 
  I detected the presence of m6A in T. brucei RNA and DNA, in both bloodstream and 
procyclic life stages. The levels are regulated in two different biological conditions. First, I observed 
that during differentiation from bloodstream to procyclic form the levels increased twelve hours after 
inducing differentiation. This time window correlates with the transition between the arrested stumpy-
like cells, in the first hours of differentiation, to growing procyclic cells. This correlation suggests that 
this modification could have a role in this transition from stumpy-like to procyclic forms. Second, I 
also observed that an increase in cell density also lead to an increase in m6A levels in RNA, suggesting 
a role of this RNA modification in response to high density stress. 
  In the genome of T. brucei is encoded a protein that, due to the presence of a 
characteristic conserved motif, is a plausible m6A methyltransferase. However the generation of a 
knockout cell line followed by measurement of m6A levels in RNA did not allow to demonstrate this 
putative function. Six proteins are encoded in T. brucei genome, forming a putative group of AlkB 
homologues group, named TbALKBH (1-6). From this group, two were selected (TbALKBH1 and 
TbALKBH2) to test the putative function of RNA m6A demethylase through knockout cell lines 
generation. Only in TbALKBH2 a small increase in m6A levels was observed, indicating that this 
candidate could be an RNA m6A demethylase. Further investigation is required to confirm this 
observation in these putative enzymes.   
 In this thesis I identified a novel modification in RNA. My initial hypothesis that m6A is 
important for post-transcriptional gene regulation in T. brucei was not confirmed, but it was also not 
disproved. The detection of m6A in RNA of two life-cycle stages and the fact that it is dynamic, are 
however strong indications that this hypothesis is plausible. The evidence presented in this thesis adds 
a new modification in T. brucei epitranscriptome, with unknown function in this parasite and raises 
diverse possibilities, including the possibility of gene regulation through RNA m6A modification.  
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Supplementary Table 1. Primers to amplify the inserts cloned in pIV vectors. In the third column, integration means that 
is the regions that flank the target genes to promote the integration in the genome. The 15 bp identical are in bold, and 
indicates the 15 bp identical to the vector backbone, G418 gene or hygromycin gene, to clone the vectors through the In-
fusion system. 
Target gene Sequence (5’3’) Product / 15 bp identical Fw/Rv 
Tb927.5.980 TATAGGGCGAATTGGGTACCACCTAAAGTGGATCCAGTGC 5’ integration/Plasmid Fw 
Tb927.5.980 CGCTACACAGCTTGAAGAGCAGAGGTAGCACAACC 5’ integration/G418 Rv 
Tb927.5.980 AACGGAAGAGTGAAACTTGTTCCCCTCCCGTAGG 3‘ integration/G418 Fw 
Tb927.5.980 ACCGCGGTGGCGGCCGCACTGTTATAGTTCCTGGCGCC 3‘ integration/Plasmid Rv 
Tb927.5.980 AGACCTTGCTGTGCCAGAGCAGAGGTAGCACAACC 5‘ integration/Hygro Rv 
Tb927.5.980 TTATCTATGCAGTATCTTGTTCCCCTCCCGTAGG 3‘ integration/Hygro Fw 
Tb927.4.460 TATAGGGCGAATTGGGTACCGCTGATGGGTGTCTTTTAACC 5’ integration/Plasmid Fw 
Tb927.4.460 CGCTACACAGCTTGAAATGAGAGATGCAGAAAGTGG 5’ integration/G418 Rv 
Tb927.4.460 AACGGAAGAGTGAAACGGTTTGTCGTTTGGTCTTG 3‘ integration/G418 Fw 
Tb927.4.460 ACCGCGGTGGCGGCCGCTCAGTGCAAAATCGAAAGCG 3‘ integration/Plasmid Rv 
Tb927.4.460 AGACCTTGCTGTGCCAATGAGAGATGCAGAAAGTGG 5‘ integration/Hygro Rv 
Tb927.4.460 TTATCTATGCAGTATCGGTTTGTCGTTTGGTCTTG 3‘ integration/Hygro Fw 
Tb927.7.6620 TATAGGGCGAATTGGGTACCTGCACTGCAGAGACGAAGG 5’ integration/Plasmid Fw 
Tb927.7.6620 CGCTACACAGCTTGAGACAATGTGAAGTTGCGAAGG 5’ integration/G418 Rv 
Tb927.7.6620 AACGGAAGAGTGAAAGAAGAGGAGCGTTGCTGTGG 3‘ integration/G418 Fw 
Tb927.7.6620 ACCGCGGTGGCGGCCGCCCACCTTCGGCTAGTGTTGG 3‘ integration/Plasmid Rv 
Tb927.7.6620 AGACCTTGCTGTGCCGACAATGTGAAGTTGCGAAGG 5‘ integration/Hygro Rv 
Tb927.7.6620 TTATCTATGCAGTATGAAGAGGAGCGTTGCTGTGG 3‘ integration/Hygro Fw 
G418 TCAAGCTGTGTAGCGCACG Gene Fw 
G418 TTTCACTCTTCCGTTGCACC Gene Rv 
Hygromycin  GGCACAGCAAGGTCTTCTG Gene Fw 
Hygromycin ATACTGCATAGATAACAAACGC Gene Rv 
 
 
Supplementary Table 2. Primers that hybridize upstream and downstream of the target locus, outside of the integration 
regions. 
Target Gene 
Primers 
Foward Reverse 
Tb927.5.980 GTTCGGAAAAGGAAGGATGC AGGATTGGTATCCCCACTGC 
Tb927.4.460 GCAGAGGAGGAGACGGAGG CGGTTCCGTTGTGCAGTCC 
Tb927.7.6620 CCAAGTAAGCGGTTAGGAGG CTCCGCCGCTTTAATTCC 
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Supplementary Table 3. Primers to amplify the integration regions in knockout cell lines. 
 
 
 
Supplementary Table 4. Primers to sequence the inserts cloned in pIV vectors.# primer used only in pIV5 sequencing. 
Plasmid  Foward  Reverse 
pIV1,pIV3 
and pIV5 
TAATACGACTCACTATAGGG AATTAACCCTCACTAAAGGG 
CTTGCCGAATATCATGGTGGA --- 
ATCGCCTTCTATCGCCTTC --- 
ATGGATTGCACGCAGGTTC --- 
AACGGAAGAGTGAAAGAAGAGGAGCGTTGCTGTGG# --- 
pIV2,pIV4 
and pIV6 
TAATACGACTCACTATAGGG AATTAACCCTCACTAAAGGG 
CCTGACCTATTGCATCTCCC ATACTGCATAGATAACAAACGC 
GGCACAGCAAGGTCTTCTG --- 
 
 
 
 
 
 
 
 
 
 
Substrate Integration Foward Reverse 
Expected 
Size (bp) 
IV2 5’ NEO GTTCGGAAAAGGAAGGATGC ACCGTAAAGCACGAGGAAGC 1406 
IV2 3’ NEO CTTGCCGAATATCATGGTGGA AGGATTGGTATCCCCACTGC 839 
IV2 5’ HYG GTTCGGAAAAGGAAGGATGC GTCGGTTTCCACTATCGGCG 1614 
IV2 3’ HYG GCCGATAGTGGAAACCGAC AGGATTGGTATCCCCACTGC 759 
IV4 5’ NEO GCAGAGGAGGAGACGGAGG ACCGTAAAGCACGAGGAAGC 1347 
IV4 3’ NEO CTTGCCGAATATCATGGTGGA CGGTTCCGTTGTGCAGTCC 841 
IV4 5’ HYG GCAGAGGAGGAGACGGAGG GTCGGTTTCCACTATCGGCG 1555 
IV4 3’ HYG GCCGATAGTGGAAACCGAC CGGTTCCGTTGTGCAGTCC 763 
IV6 5’ NEO CCAAGTAAGCGGTTAGGAGG ACCGTAAAGCACGAGGAAGC 1807 
IV6 3’ NEO CTTGCCGAATATCATGGTGGA CTCCGCCGCTTTAATTCC 1095 
IV6 5’ HYG CCAAGTAAGCGGTTAGGAGG GTCGGTTTCCACTATCGGCG 2015 
IV6 3’ HYG GCCGATAGTGGAAACCGAC CTCCGCCGCTTTAATTCC 1015 
69 
 
 
 
 
 
Supplementary figure 1. Correspondence of amino acid properties and colour in multiple sequence alignments. Colouring 
scheme is from Chroma program with black and white default settings.     
 
 
 
 
